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BACKGROUND	  
Renal	   artery	   stenosis	   (RAS)	   is	   a	   vascular	   lesion	   causing	   narrowing	   of	   the	   renal	   artery	   thereby	  
impairing	  blood	  flow	  to	  the	  kidney.	  	  Atherosclerotic	  renal	  artery	  stenosis	  (ARAS)	  is	  by	  far	  the	  most	  
common	   renovascular	   lesion	   accounting	   for	   about	   90%	   of	   all	   renal	   artery	   lesions1	   and	   typically	  
involving	  the	  proximal	  third	  of	  the	  renal	  artery	  including	  the	  aorta	  and	  ostium.	  	  Other	  less	  frequent	  
causes	  of	  RAS	  are	  listed	  in	  Table	  1.	  	  
	  
Table	  1:	  Major	  causes	  of	  vascular	  occlusion	  producing	  renovascular	  hypertension2	  
Unilateral	  disease	  
Unilateral	  atherosclerotic	  renal-­‐artery	  stenosis	  





Renal	  artery	  aneurysm	  
Arterial	  embolus	  
Arteriovenous	  fistula	  (congential/traumatic)	  
Segmental	  arterial	  occlusion	  (post-­‐traumatic)	  
Extrinsic	  compression	  of	  renal	  artery	  (e.g.	  pheochromocytoma)	  
Renal	  compression	  (e.g.	  metastatic	  tumor)	  
Bilateral	  disease	  or	  solitary	  functioning	  kidney	  
Stenosis	  to	  a	  solitary	  functioning	  kidney	  
Bilateral	  renal	  arterial	  stenosis	  
Aortic	  coarctation	  
Systemic	  vasculitis	  (e.g.	  Takayasu’s,	  polyarteritis)	  
Atheroembolic	  disease	  
Vascular	  occlusion	  due	  to	  endovascular	  aortic	  stent	  graft	  
	  
The	   prevalence	   of	   ARAS	   increases	   with	   age:	   significant	   ARAS	   can	   be	   detected	   in	   6.8%	   of	  
community-­‐based	  subjects	  above	  age	  65	  years3.	  	  It	  also	  increases	  with	  clinically	  manifest	  disease	  in	  
the	   coronary	   arteries	   (18-­‐20%),	   the	   aorta,	   or	   peripheral	   vascular	   beds	   (35-­‐50%);	   patients	   with	  
refractory	  congestive	  heart	  failure	  and/or	  end-­‐stage	  renal	  disease	  may	  have	  demonstrable	  ARAS	  in	  
40–50%	  of	  cases,	  as	  recently	  reviewed4	  (Table	  2).	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Table	  2:	  Prevalence	  of	  Atherosclerotic	  Renal	  Artery	  Stenosis	  in	  Different	  Subgroups5	  	  
Subgroups	   Prevalence	  of	  ARAS	  (>60%	  of	  renal	  artery	  lumen)	  
General	  population	  	  
Age	  >65	  years	  (Doppler)	  	  
Healthy	  kidney	  donors	  	  
Chronic	  kidney	  disease	  	  
Suspicion	  of	  renovascular	  hypertension	  
Coronary	  angiography	  	  
ESRD	  	  
Peripheral	  arterial	  disease	  
Abdominal	  aortic	  aneurysm	  
Elderly	  with	  CHF	  	  
Refractory	  CHF	  	  






19%-­‐24%	  (7%	  bilateral)	  






Note:	  Please	  note	  that	  data	  are	  based	  on	  heterogeneous	  studies	  with	  different	  methods	  of	  assessment.	  
Abbreviations:	  CHF,	  congestive	  heart	  failure;	  CKD,	  chronic	  kidney	  disease;	  ESRD,	  end-­‐stage	  renal	  disease.	  
	  
Despite	   antihypertensive	   drug	   therapy	   and	   control	   of	   risk	   factors	   for	   atherosclerosis,	   ARAS	   is	   a	  
progressive	  disease,	  leading	  to	  renal	  ischemia	  and	  loss	  of	  renal	  function6.	  
Pathophysiology	  and	  clinical	  presentations	  
The	   clinical	   spectrum	  of	  ARAS	   is	   broad	  and	   since	  RAS	   can	  be	   ‘silent’,	   it	  might	   go	  undetected	  or	  
become	   manifest	   as	   renovascular	   hypertension,	   ischemic	   nephropathy,	   and	   recurrent	   ‘flash’	  
pulmonary	  edema	  (Fig.	  1).	  	  	  
	  
Fig.	  1.	  Manifestations	  of	  renal	  arterial	  disease.	  CV,	  cardiovascular;	  MR,	  magnetic	  resonance;	  PRA,	  plasma–
renin	  activity;	  RAS,	  renal	  artery	  stenosis2.	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ARAS	   is	   a	   common	   cause	   of	   secondary	   hypertension.	   	   Unilateral	   experimental	   renovascular	  
disease	  with	   a	   functioning	   “contralateral	   kidney”	   that	   excretes	   sodium	   as	   function	   of	   “pressure	  
natriuresis”	   (identified	   as	   2-­‐kidney-­‐1-­‐clip	   hypertension)	   serves	   as	   a	  major	  model	   of	   angiotensin-­‐
dependent	  hypertension.	  	  This	  theory	  dates	  back	  to	  the	  1930s,	  when	  Goldblatt	  et	  al	  performed	  a	  
series	  of	  studies	  examining	  the	  impact	  of	  unilateral	  and	  bilateral	  RAS	  on	  blood	  pressure	  (BP)2	  (Fig.	  
2).	  	  
	  
Fig.	  2.	  Adaptive	  mechanism	  in	  two-­‐kidney,	  one-­‐clip	  Goldblatt	  hypertension.	  Cont=	  contralateral,	  Kd=kidney,	  
PRA=	  plasma	  renin	  activity.	  
	  
By	  clamping	  one	  renal	  artery	   in	  dogs,	  Goldblatt	  et	  al	  demonstrated	  a	  systemic	  pressor	  effect:	   in	  
the	   early	   stages	  BP	   increases	  within	   hours	   after	   clipping,	  with	  maximum	   levels	   reached	   at	   later	  
stages	   (approximately	   the	  36th	  week).	   	  By	  contrast,	   renin	   levels	  are	  overtly	  elevated	  only	   in	   the	  
early	  stages,	  with	  gradual	  return	  to	  baseline.	  	  This	  might	  explain	  why	  at	  the	  time	  of	  diagnosis,	  as	  
many	   as	   one-­‐third	   of	   patients	   with	   renovascular	   hypertension	   do	   not	   have	   high	   plasma	   renin,	  
either	   in	   the	  peripheral	   or	   in	   renal	   vein	  blood	   from	   the	   affected	   side8.	   	   Activation	  of	   the	   renin-­‐
angiotensin-­‐aldosterone	  system	  (RAAS)	  is	  transient	  and	  leads	  to	  recruitment	  of	  additional	  pressor	  
pathways,	   including	   oxidative	   stress,	   sympatho-­‐adrenergic	   activation,	   and	   impaired	   vasodilatory	  
responses	  both	  within	  the	  renal	  and	  systemic	  microcirculation9.	   	   Instead,	  the	  mechanism	  behind	  
bilateral	  or	  unilateral	  RAS	  with	  a	  solitary	  kidney	  is	  due	  to	  extracellular	  fluid	  overload	  secondary	  to	  
decreased	  diuresis	  rather	  than	  a	  renin-­‐mediated	  mechanism.	  	  	  
It	  should	  be	  emphasized	  that	  the	  release	  of	  circulating	  renin	  depends	  on	  a	  substantial	  reduction	  in	  
kidney	  perfusion	  pressure.	  	  Unilateral	  or	  bilateral	  hypersecretion	  of	  renin	  is	  associated	  with	  80%	  or	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greater	   reduction	   of	   renal	   artery	   lumen	   diameter10.	   	   De	   Bruyne	   at	   al	   by	  means	   of	   renal	   artery	  
balloon	  occlusion	   in	  humans	  and	  expressing	  stenosis	   severity	  as	   the	   ratio	  of	  distal	  pressure	   (Pd)	  
corrected	  for	  aortic	  pressure	  (Pa),	  demonstrated	  a	  Pd/Pa	  ratio	  of	  0.90	  is	  the	  threshold	  level	  below	  
which	  the	  stenosis	  is	  likely	  responsible	  for	  an	  up-­‐regulation	  of	  renin	  production	  and	  a	  Pd/Pa	  ratio	  
of	  0.90	  corresponds	  approximately	  to	  a	  systolic	  gradient	  of	  25	  mm	  Hg11	  (Fig.3).	  	  	  
	  
	  
Fig.	  3.	  Relationship	  between	  the	  individual	  values	  of	  mean	  aortic	  pressure	  (Pd)/mean	  pressure	  distal	  to	  the	  
renal	  artery	  stenosis	  (Pa)	  ratios	  and	  the	  corresponding	  systolic	  pressure	  gradients	  (closed	  circles)	  and	  mean	  
pressure	  gradients	  across	  the	  stenosis	  (open	  circles)11.	  
	  
The	  assessment	  of	  pressure	  gradient	  is	  a	  conflicting	  item	  and	  the	  optimal	  method	  for	  determining	  
it	   has	   not	   been	   established.	   	   Currently,	   translesional	   pressure	   gradients	   are	   often	  measured	   by	  
placing	  a	  4Fr	  or	  larger	  catheter	  distal	  to	  the	  lesion	  while	  simultaneously	  measuring	  pressure	  in	  the	  
aorta.	   	   Unfortunately,	   the	   catheter	   itself	   may	   partially	   obstruct	   flow	   and	   thereby	   artifactually	  
increase	  the	  pressure	  gradient12.	  	  By	  reducing	  the	  size	  of	  the	  device	  used	  to	  measure	  the	  pressure	  
using	  a	  0.014’’	  guidewire,	  Coyler	  demonstrated	  that	  the	  translesional	  pressure	  gradient	  obtained	  
	   6	  
by	  pressure-­‐sensing	  guidewire	  correlate	  more	  strongly	  with	  angiographic	  minimal	  lumen	  diameter	  
(r2	  =	  0.801)	  than	  those	  obtained	  by	  4	  Fr	  catheter	  (r2	  =	  0.360)12.	  	  	  
When	   reduced	   kidney	   perfusion	   activates	   pressor	   mechanisms,	   systemic	   blood	   pressure	   often	  
rises,	   sometimes	   leading	   to	   acceleration	  of	   pre-­‐existing	  essential	   hypertension.	   	  As	   a	   result,	   the	  
clinical	   manifestations	   of	   ARAS	   most	   commonly	   develop	   in	   previously	   treated	   hypertensive	  
subjects.	  	  
Ischemic	  nephropathy	  is	  due	  to	  decreased	  perfusion	  caused	  by	  the	  obstruction	  of	  the	  renal	  artery	  
with	   subsequent	   excretory	   dysfunction.	   	   The	   cause	   of	   ischemic	   nephropathy	   has	   not	   been	   fully	  
elucidated	   and	   it	   has	   to	   be	   underlined	   that,	   in	   most	   cases,	   ARAS	   develops	   in	   a	   setting	   of	  
preexisting	   vascular	   changes	   affecting	   the	   kidney	   as	   a	   result	   of	   aging,	   hypertension,	   diabetes,	  
dyslipidemia,	  and	  occasionally	  atheroembolism.	  	  The	  severity	  of	  stenosis	  has	  not	  been	  correlated	  
with	  kidney	  function,	  decline	  in	  glomerular	  filtration,	  or	  results	  of	  revascularization13,14,	  indicating	  
that	  other	  mechanisms	  are	  implicated	  in	  ischemic	  nephropathy.	  
Several	   pathways	   have	   been	   proposed	   to	   explain	   how	   a	   hemodynamically	   significant	   lesion	  
ultimately	   results	   in	   interstitial	   fibrosis	   (Fig.	   4	   and	   5).	   	   Recurrent	   local	   ischemia	   and	   global	  
hypoperfusion	  cause	  tubulointerstitial	  injury	  and	  microvascular	  damage	  and	  RAAS	  activation	  with	  
subsequent	  vasoconstriction.	  	  In	  addition	  to	  kidney	  hypoperfusion,	  systemic	  atherosclerosis	  leads	  
to	  activation	  of	  proinflammatory	  cytokines	  and	  oxidative	  stress,	  causing	  microvascular	  rarefaction,	  
inflammatory	   infiltration,	   glomerulosclerosis,	   and	   tubulointerstitial	   fibrosis,	   which	   lead	   to	  
proteinuria	  and	  glomerular	  filtration	  reduction.	  	  The	  renal	  lesion	  in	  ischemic	  nephropathy	  usually	  
is	  accompanied	  by	  hypertensive	  nephrosclerosis	  and	  atheroembolic	  disease,	  which	  contribute	  to	  
the	  reduction	  of	  glomerular	  filtration15,16.	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Fig.	   4.	   Pathophysiology	   of	   ischemic	   nephropathy.	   Abbreviations:	   AV,	   arteriovenous;	   GFR,	   glomerular	  
filtration	  rate;	  LDL,	  low-­‐density	  lipoprotein.	  Dotted	  line:	  protective	  mechanisms16.	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Fig.	   5.	   A	   Micro–computed	   tomographic	   images	   showing	   microvascular	   loss	   in	   the	   poststenotic	   kidney,	  
which	  was	   rescued	   using	  mesenchymal	   stem	   cell–derived	   extracellular	   vesicles.	  B	   Schematic	   of	   injurious	  
mechanisms	  activated	  in	  the	  poststenotic	  kidney	  in	  ARAS,	  and	  experimental	  therapeutic	  interventions	  that	  
can	  potentially	  blunt	  them17.	  
	  
Ischemic	  nephropathy	  is	  particularly	  interesting	  in	  the	  light	  of	  recent	  results	  of	  randomized	  clinical	  
trials	  (RCTs),	  which	  failed	  to	  demonstrate	  a	  superiority	  of	  revascularization	  compared	  to	  medical	  
therapy	   alone.	   	   This	   could	   be	   in	   part	   explained	   by	   ischemic	   nephropathy	   and	   renal	   interstitial	  
fibrosis,	  which	  develop	  beyond	  a	  vascular	  lesion	  and	  could	  make	  revascularization	  ineffective.	  	  	  
Saad	   et	   al	   recently	   demonstrated	   that	   severe	   renovascular	   disease	   is	   associated	   with	   tissue	  
hypoxia	   and	   increased	   renal	   venous	   markers	   of	   inflammatory	   cytokines	   (monocyte	  
chemoattractant	  protein-­‐1	  and	  tumor	  necrosis	   factor-­‐α)	  and	  tissue	   injury	   (neutrophil	  gelatinase-­‐
A	  
B	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associated	  lipocalin).	  	  Revascularization	  might	  reduce	  hypoxia	  and	  partially	  restore	  blood	  flow,	  but	  
fails	  to	  alter	  the	  markers	  of	  inflammation,	  suggesting	  that	  additional	  measures	  may	  be	  needed	  to	  
reverse	  the	  process	  of	  kidney	  injury18.	  
Eirin	   and	   coworkers	   evaluated	   the	   relationship	   between	   net	   renovascular	   cytokine	   release	   and	  
tissue	   inflammation	   in	   pigs’	   post-­‐stenotic	   kidney.	   	   Net	   release	   of	   TNF-­‐α,	   IF-­‐γ,	   and	   MCP-­‐1	   was	  
higher	  in	  RAS	  compared	  with	  normal	  and	  to	  the	  contralateral	  kidney19.	   	  More	  recently	  Eirin	  et	  al	  
hypothesized	   that	   chronic	   renal	   damage	   involves	   mitochondrial	   injury	   and	   that	   mitochondrial	  
protection	  would	  reduce	  renal	  fibrosis	  and	  dysfunction	  in	  ARAS	  pigs.	  	  They	  studied	  28	  pigs	  after	  10	  
weeks	  of	  ARAS	  or	  sham,	  treated	  with	  vehicle	  or	  Bendavia,	  a	  tetrapeptide	  that	  preserves	  cardiolipin	  
content	   in	   the	   mitochondrial	   inner	   membrane.	   	   They	   found	   that	   Bendavia	   restored	   cardiolipin	  
content	  in	  ARAS	  and	  improved	  vascular	  density,	  oxygenation,	  renal	  blood	  flow,	  and	  GFR	  and	  that	  
oxidative	   stress	   and	   fibrosis	   were	   improved,	   and	   renovascular	   endothelial	   function	   normalized	  
both	  in	  vivo	  and	  in	  vitro20.	  
Ebrahimi	   et	   al	   tested	   the	   hypothesis	   that	   addition	   of	   mesenchymal	   stem	   cells	   (MSC)	   to	  
percutaneous	  transluminal	  renal	  angioplasty	  (PTRA)	  can	  restore	  stenotic	  kidney	  medullary	  tubular	  
transport	   function	   and	   attenuate	   its	   remodeling	   in	   swine.	   	   MSC	   delivery	   in	   addition	   to	   PTRA	  
reduces	   inflammation,	   fibrogenesis	   and	   vascular	   remodeling,	   and	   restores	   oxygen-­‐dependent	  
tubular	  function	  in	  the	  stenotic-­‐kidney	  medulla21,22.	  
Most	   recent	   researches	   are	   focused	   on	  microRNAs,	   small	   non-­‐coding	   RNAs	   that	   are	   important	  
regulators	  of	  gene	  expression	  and	  have	  been	  implicated	  in	  atherosclerosis.	  	  Park	  et	  al	  hypothesize	  
that	  it	  might	  be	  implicated	  in	  modulating	  renal	  injury	  in	  ARAS23.	  
These	   recent	   studies	  may	   in	   part	   explain	   the	   failure	   of	   RCTs	   to	   demonstrate	   the	   superiority	   of	  
percutaneous	  transluminal	  renal	  angioplasty	  plus	  stenting	  (PTRAS)	  over	  medical	  therapy	   in	  ARAS	  
treatment	   in	   whom,	   beyond	   the	   simple	   restore	   of	   blood	   flow,	   is	   also	   implicated	   an	   ischemic	  
alteration	  of	  the	  renal	  tissue.	  	  The	  failure	  of	  renal	  artery	  revascularization	  to	  restore	  renal	  function	  
in	  ARAS	  provides	  the	  impetus	  to	  explore	  underlying	  mechanisms	  and	  treat	  the	  poststenotic	  kidney	  
directly17.	   	   Further	   studies	   are	   needed	   to	   demonstrate	   the	   benefit	   of	   the	   addition	   of	   a	   renal	  
ischemia	   “protective”	   vehicle	   to	   PTRAS	   and	   identification	   of	   the	   basic	  mechanisms	   that	   lead	   to	  
kidney	  tissue	  injury	  in	  ARAS	  can	  assist	  in	  the	  development	  of	  targeted	  therapies.	  
ARAS	  may	  either	  cause	  or	  exacerbate	  unstable	  angina	  and	  congestive	  heart	  failure.	  	  A	  rapid	  rise	  in	  
arterial	   pressure	   caused	   by	   peripheral	   arterial	   vasoconstriction	   combined	   with	   reduced	   renal	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perfusion	   and	   enhanced	   sodium	   reabsorption	   can	   lead	   to	   rapidly	   developing	   circulatory	  
congestion	  (flash	  pulmonary	  edema).	  	  This	  phenomenon	  was	  first	  reported	  by	  Pickering	  in	  198824.	  	  
Flash	  pulmonary	  edema	  does	  occur	   in	  unilateral	  RAS,	  but	   tends	   to	  occur	  more	  often	   in	  patients	  
with	   bilateral	   RAS	   (Fig.	   6).	   	   Acute	   angiotensin-­‐mediated	   increase	   in	   afterload	   is	   the	  
physiopathologic	  mechanism	   that	   explains	   unstable	   angina	   in	   RAS	   due	   to	   increased	  myocardial	  




Fig.	  6.	  The	  Pickering	  Syndrome.	  Three	  main	  pathophysiological	  mechanisms	  contribute	  to	  the	  development	  
of	  flash	  pulmonary	  oedema:	  defective	  pressure	  natriuresis	  with	  sodium	  and	  fluid	  retention,	   increased	  left	  
ventricular	  end-­‐diastolic	  pressure	  associated	  with	  left	  ventricular	  hypertrophy	  and	  stiffening,	  and	  failure	  of	  
the	  pulmonary	  capillary	  blood–gas	  barrier.	  RAAS,	  renin–angiotensin–aldosterone	  system;	  SNS,	  sympathetic	  




	   11	  
Diagnosis	  
According	   to	   the	  American	  College	  of	  Cardiology/American	  Heart	  Association	   (ACC/AHA)	  Clinical	  
Practice	  Guidelines26	  clinicians	  may	  perform	  diagnostic	  studies	  to	  identify	  clinically	  significant	  RAS	  
(class	  I	  with	  level	  of	  evidence	  B)	   in	  patients	  with	  the	  onset	  of	  hypertension	  before	  the	  age	  of	  30	  
years	   or	   after	   the	   age	   of	   55	   years,	   in	   patients	   with	   accelerated,	   resistant,	   or	   malignant	  
hypertension	   (level	   of	   evidence	   C),	   in	   patients	   with	   new	   azotemia	   or	   worsening	   renal	   function	  
after	  the	  administration	  of	  an	  ACE	  inhibitor	  or	  an	  angiotensin	  receptor	  blocking	  agent,	  in	  patients	  
with	  an	  unexplained	  atrophic	  kidney	  or	  a	  discrepancy	  in	  size	  between	  the	  2	  kidneys	  greater	  than	  
1.5	  cm	  and	  in	  patients	  with	  sudden,	  unexplained	  pulmonary	  edema.	  
The	  performance	  of	  diagnostic	  studies	  to	  identify	  RAS	  is	  reasonable	  (class	  IIa	  level	  of	  evidence	  B)	  in	  
patients	  with	   unexplained	   renal	   failure,	   including	   individuals	   starting	   renal	   replacement	   therapy	  
(dialysis	  or	   renal	   transplantation)	   and	  may	  be	   reasonable	   (Class	   IIb)	   in	  patients	  with	  multivessel	  
coronary	  artery	  disease	  and	  none	  of	  the	  clinical	  clues	  or	  peripheral	  artery	  disease	  at	  the	  time	  of	  
arteriography	   (level	  of	  evidence:	  B)	  and	   in	  patients	  with	  unexplained	  congestive	  heart	   failure	  or	  
refractory	  angina	  (level	  of	  evidence:	  C).	  
According	   to	   the	   ACC/AHA	   guidelines,	   duplex	   ultrasonography,	   computed	   tomographic	  
angiography	   (CTA),	   and	  magnetic	   resonance	   angiography	   (MRA)	   all	   received	   a	   class	   I	   indication	  
(level	  B	  evidence)	  as	  a	  screening	  test	  to	  establish	  the	  diagnosis	  of	  RAS26.	  	  
Duplex	   ultrasonography	   allows	   direct	   visualization	   of	   the	   renal	   arteries	   (B-­‐mode	   imaging)	   and	  
Doppler	  velocity	  measurements	  of	  blood	  flow.	  	  The	  advantages	  of	  this	  technique	  are	  that	  it	  is	  not	  
invasive,	   is	  not	  affected	  by	  medications,	   is	   low-­‐cost	  and	  does	  not	  require	  the	  use	  of	   intravenous	  
contrast.	   	   Duplex	   is	   particularly	   useful	   for	   identifying	   restenosis	   of	   metallic	   stents	   after	  
implantation.	   	   However,	   Duplex	   is	   not	   without	   limitations.	   	   The	   test	   is	   time-­‐consuming	   with	  
prolonged	  examination	  times,	  it	  can	  be	  technically	  challenging	  in	  obese	  patients	  or	  in	  the	  presence	  
of	   abdominal	   gas,	   and	   is	   also	   significantly	   operator-­‐dependent.	   	   Detection	   of	   stenosis	   is	  
determined	  by	  the	  measurement	  of	  a	  high	  peak	  systolic	  velocity	  (PSV)	  (>180	  or	  >200	  cm/second)	  
or	  by	  the	  renal	  to	  aortic	  ratio,	  which	  is	  calculated	  by	  dividing	  the	  PSV	  of	  the	  renal	  artery	  by	  the	  PSV	  
of	  the	  adjacent	  aorta	  (normal	  ratio	  <3.5).	   	  Duplex	  may	  be	  used	  also	  to	  measure	  the	  renal	  artery	  
resistive	  index	  (RRI).	  	  An	  increased	  RRI	  suggests	  structural	  abnormalities	  in	  the	  small	  blood	  vessels	  
e.g.	   in	   the	   context	   of	   longstanding	   hypertension	   associated	   with	   nephrosclerosis	   or	  
glomerulosclerosis.	   	   There	   are	   conflicting	   reports	   regarding	   the	   usefulness	   of	   RRI	   to	   predict	   the	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response	  to	  revascularization.	   	  Radermacher	  et	  al	   in	  their	  retrospective	  study	  demonstrated	  that	  
an	   elevated	   resistance	   index	   >0.80	   predicted	   a	   lack	   of	   improvement	   in	   terms	   of	   mean	   arterial	  
pressure	  and	  renal	  function,	  but	  this	  study	  had	  some	  limitations	  such	  as	  the	  retrospective	  design	  
and	  the	   inclusion	  of	  a	   large	  majority	  of	  patients	  who	  received	  balloon	  angioplasty	  without	  stent	  
placement27.	  	  Zeller	  et	  al	  analyzed	  a	  subgroup	  of	  patients	  treated	  with	  stent	  angioplasty	  for	  severe	  
(≥70%)	   ostial	   ARAS	   who	   had	   diabetes	   mellitus	   and	   nephrosclerosis.	   	   They	   did	   not	   find	   any	  
difference	  in	  terms	  of	  improvement	  in	  mean	  blood	  pressure	  in	  patients	  with	  RRI	  <0.7	  or	  RRI	  >0.8	  
and	   serum	   creatinine	   decreased	   significantly	   in	   both	   subgroups	   during	   follow-­‐up28.	   	   Therefore	  
ACC/AHA	   guidelines	   concluded	   that	   RRI	   may	   prove	   useful	   in	   identifying	   severe	   parenchymal	  
disease,	  but	  could	  not	  be	  considered	  as	  predictors	  of	  an	  adverse	  or	  beneficial	  clinical	  outcome	  to	  
renal	  revascularization26.	  
CTA	   has	   proven	   to	   be	   the	   most	   frequent	   diagnostic	   test	   used	   to	   identify	   RAS.	   	   Multidetector	  
computed	  tomography	  (MDCT)	  increased	  speed	  of	  image	  acquisition	  as	  well	  as	  spatial	  resolution.	  	  
The	  disadvantages	  are	   the	  difficulties	   in	  estimating	   the	  degree	  of	   stenosis	  with	  extensive	   vessel	  
wall	   calcification	  and	   the	   requirement	  of	  potentially	  nephrotoxic	   iodinated	  contrast	   (100	   to	  150	  
cc),	  especially	  harmful	   in	  ARAS	  patients,	  a	  population	  with	   increased	  prevalence	  of	   renal	   failure.	  	  
Compared	   to	  MRA,	   CTA	   has	   higher	   spatial	   resolution	   and	   less	   artifacts	   due	   to	   implanted	  metal	  
stents.	  	  
MRA	   requires	   intravascular	   contrast	   to	   enhance	   the	   imaging	   of	   blood	   vessels;	   however,	  
gadolinium	  contrast	   is	   less	  nephrotoxic	  than	  the	   ionized	  contrast	  used	  for	  CTA.	   	  Therefore,	  MRA	  
can	   be	   performed	   in	   patients	  with	   some	   degree	   of	   renal	   failure	   (although	   not	   in	   patients	  with	  
severe	   renal	   insufficiency	  or	   those	  undergoing	  dialysis	   treatment	  due	   to	   the	   risk	  of	  nephrogenic	  
systemic	   fibrosis	   with	   gadolinium	   contrast	   in	   subjects	   with	   a	   GFR	   <30	   mL/minute/1.73	   m2),	  
congestive	  heart	  failure,	  and	  dye	  allergy.	   	  The	  disadvantages	  are	  the	  cost,	  the	  impossibility	  to	  be	  
used	  in	  patents	  with	  pacemakers	  or	  other	  metallic	  objects	  and	  to	  evaluate	  in-­‐stent	  restenosis.	  
Arterial	  angiography	  remains	  the	  gold	  standard	  for	  the	  diagnosis	  of	  RAS,	  and	  is	  typically	  used	  only	  
after	  a	  positive	  noninvasive	  screening	  test.	  	  Although	  more	  invasive	  than	  other	  techniques,	  the	  risk	  
of	   complications	   is	   low	   (access-­‐related	   complications,	   embolization,	   contrast-­‐related	   allergic	  
reactions,	  and	  contrast-­‐induced	  nephropathy).	  
Receiving	   a	   Class	   III	   recommendation,	   captopril	   scintigraphy,	   selective	   renal	   vein	   renin	  
measurements,	  plasma	  renin	  activity,	  and	  captopril	   test	   (measurement	  of	  plasma	  renin	  activity	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after	  captopril	  administration),	  are	  not	  recommended	  as	  a	  screening	  test	  to	  diagnose	  RAS.	  	  Renal	  
vein	  renin	  measurements	  may	  have	  some	  utility	  in	  establishing	  the	  indication	  for	  nephrectomy	  in	  
patients	  with	  renal	  artery	  occlusion	  rather	  than	  in	  identifying	  patients	  with	  RAS	  who	  may	  benefit	  
from	  revascularization.	  	  
Treatment	  
Crucial	   in	   ARAS	   treatment	   is	   an	   adequate	   risk	   factors’	   control	   for	   all	   patients.	   	   This	   includes	  
glycemic	  control	  optimization,	  cholesterol	  decrease,	  smoking	  cessation,	  blood	  pressure	  reduction,	  
and	   primary	   prevention	   with	   antiplatelets.	   	   According	   to	   ACC/AHA	   guidelines	   (Table	   3),	   ACE	  
inhibitors,	  angiotensin	  receptor	  blockers,	  calcium	  channel	  blockers,	  and	  beta-­‐blockers	  all	  receive	  a	  
class	   I	   indication	   for	   the	   treatment	   of	   hypertension	   associated	   with	   RAS26.	   	   The	   role	   of	   ACE	  
inhibitors/angiotensin	   receptor	   blockers	   is	   crucial	   in	   ARAS	   treatment	   because	   of	   blocking	   RAAS	  
system	  but	  specific	  attention	  has	   to	  be	  paid	   in	  patients	  with	  solitary	   functioning	  kidneys,	  severe	  
bilateral	   stenoses,	   or	   advanced	   chronic	   kidney	   disease	   for	   the	   potential	   to	   induce	   acute	   renal	  
failure.	  	  Under	  these	  conditions	  a	  rise	  in	  creatinine	  develops	  both	  because	  blood	  flow	  is	  affected	  
and	  because	  angiotensin	  II	  supports	  filtration.	  	  Hence,	  the	  loss	  of	  glomerular	  filtration	  rate	  (GFR)	  
reflects	   a	   functional	   signal	   that	   blood	   flow	   is	   threatened	   and	   filtration	   requires	   the	   supportive	  
action	  of	  angiotensin.	  	  Most	  patients	  with	  hemodynamically	  relevant	  ARAS	  tolerate	  RAAS	  blockade	  
without	  adverse	  effects.	   	  Recommendations	   for	   the	  use	  of	   these	  agents	   include	  re-­‐evaluation	  of	  
serum	  creatinine	  and	  potassium	  level	  soon	  (within	  a	  week)	  after	  initiating	  therapy,	  particularly	  in	  
patients	  with	  reduced	  kidney	  function29.	  
PTRAS	  is	  the	  treatment	  of	  choice	  for	  symptomatic	  ARAS.	  	  It	  had	  been	  demonstrated	  that	  balloon	  
angioplasty	  alone	  was	  hampered	  by	  lower	  procedural	  success	  rate	  and	  a	  higher	  restenosis	  rate30-­‐
34.	   	  The	  superiority	  of	   renal	  stent	  placement	  over	  balloon	  angioplasty	  was	  confirmed	   in	  a	  RCT	   in	  
hypertensive	   patients	   by	   van	  de	  Ven	   and	   coworkers35,	   in	  whom	  patients	  with	   ostial	   ARAS	  were	  
assigned	   to	   receive	  PTRA	  or	  PTRAS.	   	   Primary	   success	   rate	   (<50%	   residual	   stenosis)	   of	   PTRA	  was	  
57%	  compared	  with	  88%	  for	  PTRAS	  and	  at	  6	  months,	  the	  primary	  patency	  rate	  was	  29%	  for	  PTRA,	  
and	  75%	  for	  PTRAS.	  	  Restenosis	  after	  a	  successful	  primary	  procedure	  occurred	  in	  48%	  of	  patients	  
for	  PTRA	  and	  14%	  for	  PTRAS.	  
Endovascular	  treatment	  is	  considered	  in	  case	  of	  hemodynamically	  significant	  stenosis.	  	  According	  
to	  ACC/AHA	  guidelines26	  ‘significant	  stenosis’	  is	  defined	  as	  a	  narrowing	  in	  lumen	  diameter:	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(a)	  ≥50%	  and	  <70%	  by	  visual	  estimation	  with	  a	  peak	  translesional	  gradient	  (measured	  with	  a	  less	  
than	  or	  equal	  to	  5-­‐Fr	  catheter	  or	  pressure	  wire)	  ≥20	  mm	  Hg	  or	  a	  mean	  gradient	  ≥10	  mm	  Hg,	  	  
(b)	  any	  stenosis	  ≥70%36.	  	  
Indications	  for	  PTRAS	  are	  listed	  in	  Table	  3.	  
Table	  3:	  ACC/AHA	  guidelines26	  	  
Asymptomatic	  stenosis	  
Class	  IIb	  
1. PTRAS	  may	  be	  considered	  for	  treatment	  of	  an	  asymptomatic	  bilateral	  or	  solitary	  viable	  
kidney	  with	  a	  hemodynamically	  significant	  RAS.	  (Level	  of	  Evidence:	  C)	  
2. The	  usefulness	  of	  PTRAS	  of	  an	  asymptomatic	  unilateral	  hemodynamically	  significant	  
RAS	  in	  a	  viable	  kidney	  is	  not	  well	  established	  and	  is	  presently	  clinically	  unproven.	  
(Level	  of	  Evidence:	  C)	  
Hypertension	  
Class	  IIa	  
1. PTRAS	  is	  reasonable	  for	  patients	  with	  hemodynamically	  significant	  RAS	  and	  
accelerated	  hypertension,	  resistant	  hypertension,	  malignant	  hypertension,	  
hypertension	  with	  an	  unexplained	  unilateral	  small	  kidney,	  and	  hypertension	  with	  
intolerance	  to	  medication.	  (Level	  of	  Evidence:	  B)	  
Ischemic	  nephropathy	  
Class	  IIa	  
1. PTRAS	  is	  reasonable	  for	  patients	  with	  RAS	  and	  progressive	  chronic	  kidney	  disease	  with	  
bilateral	  RAS	  or	  a	  RAS	  to	  a	  solitary	  functioning	  kidney.	  (Level	  of	  Evidence:	  B)	  
Class	  IIb	  
2. PTRAS	  may	  be	  considered	  for	  patients	  with	  RAS	  and	  chronic	  renal	  insufficiency	  with	  
unilateral	  RAS.	  (Level	  of	  Evidence:	  C)	  
Cardiac	  destabilization	  syndromes	  
Class	  I	  
1. PTRAS	  is	  indicated	  for	  patients	  with	  hemodynamically	  significant	  RAS	  and	  recurrent,	  
unexplained	  congestive	  heart	  failure	  or	  sudden,	  unexplained	  pulmonary	  edema.	  (Level	  
of	  Evidence:	  B)	  
Class	  IIa	  
2. PTRAS	  is	  reasonable	  for	  patients	  with	  hemodynamically	  significant	  RAS	  and	  unstable	  
angina.	  (Level	  of	  Evidence:	  B)	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Surgery	   for	  ARAS	   is	   limited	   to	  patients	  with	  clinical	   indications	   for	   intervention,	  especially	   those	  
with	   multiple	   small	   renal	   arteries	   or	   early	   primary	   branching	   of	   the	   main	   renal	   artery	   and	   for	  
patients	  with	  ARAS	   in	   combination	  with	  pararenal	   aortic	   reconstructions	   (in	   treatment	  of	   aortic	  
aneurysms	  or	  severe	  aortoiliac	  occlusive	  disease).	  
Previous	  randomized	  clinical	  trials	  
The	  major	  RCTs	  published	   to	  date	  have	  been	  unable	   to	  prove	  a	   clinical	   benefit	   of	   endovascular	  
revascularization	  for	  the	  treatment	  of	  ARAS.	  However,	  significant	  design	  flaws	  and	  selection	  bias	  
affect	  many	  of	  these	  studies,	  limiting	  the	  usefulness	  of	  available	  data	  (Table	  4	  and	  5).	  
Detailed	  below	  are	  the	  most	  important	  RCTs’	  bias:	  
• SELECTION	  CRITERIA	  
Most	   of	   RCTs	   included	   patients	   without	   resistant	   hypertension	   or	   with	   only	   mild	  
hypertension.	   	   The	   aforementioned	   practice	   guidelines	   recommendations26	   suggest	   that	  
PTRAS	   is	   reasonable	   for	   patients	   with	   hemodynamically	   significant	   RAS	   and	   resistant	  
hypertension,	  defined	  as	  the	  failure	  to	  achieve	  goal	  BP	  in	  patients	  who	  are	  adhering	  to	  full	  
doses	  of	  an	  appropriate	  three-­‐drug	  regimen	  that	  includes	  a	  diuretic.	  	  The	  mean	  number	  of	  
antihypertensive	   drugs	   in	   the	   patients	   recruited	   in	   these	   trials	   was	   <3	   in	   ASTRAL37,	   2	   in	  
DRASTIC38	   and	   ≤2	   in	   the	   EMMA	   study33.	   	   In	   terms	   of	   renal	   function,	   the	   EMMA	   study33	  
included	  patients	  with	  normal	  serum	  creatinine	  (mean	   levels	  103	  mcmol/L),	   in	  DRASTIC38	  
and	   in	  CORAL39	  patients	  had	  preserved	   levels	  of	  eGFR	  (63.5	  and	  58	  ml/min	  respectively).	  	  
Therefore,	  considering	  the	  preserved	  renal	  function,	  easily	  controlled	  BP	  and	  exclusion	  of	  
high	  risk	  patients	  (with	  recent	  congestive	  heart	  failure,	  unstable	  angina,	  stroke	  or	  TIA),	  the	  
RCTs	  population	  represented	  a	  ‘low-­‐risk’	  atherosclerotic	  cohort.	  	  Finally,	  the	  most	  striking	  
bias	   is	   represented	  by	   the	   following	  ASTRAL37	   inclusion	   criterion:	   “if	   the	  patient’s	  doctor	  
was	   uncertain	   that	   the	   patient	   would	   definitely	   have	   a	   worthwhile	   clinical	   benefit	   from	  
revascularization”.	  	  In	  practice,	  if	  a	  patient	  was	  thought	  to	  need	  revascularization	  within	  6	  
months,	  he	  was	  excluded.	  
• ENDPOINTS	  
Most	  of	  RCTs	  determined	  as	  primary	  endpoint	  the	  renal	  function	  but	  they	  assessed	  indexes	  
of	   global	   renal	   function	   (as	   creatinine	   and/or	   creatinine	   clearance),	   and	   not	   separate	  
estimates	   of	   GFR	   in	   the	   ischemic	   and	   the	   contralateral	   kidney.	   	   However,	   as	   a	  
hemodynamically	   significant	  RAS	   is	  expected	   to	   lower	  GFR	   in	   the	   ischemic	  kidney	  and	   to	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induce	  hyperfiltration	  in	  the	  contralateral	  kidney	  that	  is	  exposed	  to	  high	  BP,	  it	  is	  probably	  
naïve	  to	  expect	  any	  improvement	  of	  indexes	  of	  overall	  GFR	  after	  lowering	  BP	  with	  PTRAS.	  	  
Furthermore,	   the	  primary	  endpoint	   in	  ASTRAL37	  was	   the	   rate	  of	  decline	   in	   renal	   function	  
assessed	  by	  measuring	  the	  mean	  slope	  of	  the	  reciprocal	  of	  the	  serum	  creatinine	  level	  over	  
time.	   	   White	   in	   his	   well	   known	   Editor’s	   page	   “Kiss	   my	   ASTRAL”	   declared:	   “How	   can	  
revascularization	  improve	  renal	  function	  when	  25%	  of	  the	  patients	  enrolled	  in	  the	  trial	  had	  
normal	  renal	  function	  and	  another	  15%	  had	  nearly	  normal	  renal	  function?	  	  Moreover,	  the	  
hypertensive	   patients	   enrolled	   in	   this	   trial	   were	   taking	   an	   average	   of	   only	   2.8	  
antihypertensive	  medications,	  with	   BP	   averaging	   in	   the	   150/75	  mmHg	   range.	   	   Are	   these	  
patients	  likely	  to	  benefit	  from	  a	  renal	  artery	  stent?”40.	  	  In	  STAR41	  it	  is	  also	  worth	  noting	  that	  
>50%	  had	  unilateral	  disease.	  	  This	  is	  important	  because	  bilateral	  disease	  is	  usually	  required	  
to	  observe	  changes	  in	  creatinine	  clearance,	  which	  was	  the	  primary	  endpoint.	  
• DEFINITION	  OF	  SIGNIFICANT	  STENOSIS	  
The	   older	   RCTs	   included	   patients	   with	   non-­‐significant	   RAS	   according	   to	   later	   published	  
ACC/AHA	  guidelines26.	  	  In	  SNARSCG42	  and	  DRASTIC38	  RAS	  was	  defined	  as	  greater	  than	  50%,	  
indicating	  that	  many	  non-­‐hemodynamically	  significant	   lesions	  were	  treated.	   	   In	  STAR41	  of	  
the	  140	  patients,	  33%	  had	  only	  mild	  RAS	  (50%-­‐70%).	  	  In	  ASTRAL37	  41%	  had	  stenosis	  <70%.	  
• TYPE	  OF	  INTERVENTION	  
DRASTIC38	  evaluated	  only	  the	  effect	  of	  PTRA	  without	  stenting	  like	  SNRASCG42	  and	  EMMA33	  
trials	  (Table	  5).	  	  Angioplasty	  without	  stenting	  represents	  suboptimal	  treatment	  in	  stenting	  
era.	  
• ANALYSIS	  OF	  RESULTS	  
Most	   RCTs	   performed	   an	   intention-­‐to-­‐treat	   analysis	   (with	   the	   exception	   of	   EMMA33	   and	  
SNRASCG42)	   and	   the	   percentage	   of	   patients	   who	   crossed	   over	   from	   medical	   to	  
endovascular	  treatment	  was	  44%	  in	  DRASTIC38	  (because	  of	  persistent	  hypertension	  despite	  
treatment	  with	  three	  or	  more	  drugs	  or	  because	  of	  deterioration	  of	  renal	  function),	  and	  6%	  
in	   ASTRAL37	   but	   17%	   of	   those	   originally	   randomized	   to	   endovascular	   treatment	   did	   not	  
receive	  it.	  	  In	  STAR41	  12	  of	  64	  patients	  (19%)	  in	  the	  stenting	  arm	  had	  RAS	  <50%	  and	  did	  not	  
receive	   a	   stent	   but	   were	   still	   analyzed	   on	   a	   intention-­‐to-­‐treat	   basis.	   	   An	   additional	   6	  
patients	   in	   the	   stent	   arm	  did	   not	   receive	   a	   stent	   (one	   received	   balloon	   angioplasty,	   one	  
died	  before	  stent	  placement,	  two	  declined	  the	  stent,	  and	  two	  had	  technical	  failures)	  but	  all	  
were	  analyzed	  in	  endovascular	  group.	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• PERI-­‐PROCEDURAL	  ADVERSE	  EVENTS	  
In	  ASTRAL37	  the	  major	  adverse	  event	  rate	  of	  9%	  is	  fourfold	  higher	  than	  the	  2.4%	  observed	  
in	   the	  ODORI	  Registry43	  and	  the	  ASPIRE-­‐2	  Study44.	   	  During	  the	  7	  years	  of	   recruitment,	  24	  
centers	  randomized	  between	  one	  and	  five	  patients	  (42%	  of	  all	  randomized	  patients)	  and	  35	  
centers	  randomized	  10	  patients	  or	  less	  (65%	  of	  all	  randomized	  patients).	  	  This	  means	  that	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“Substantial”	  ARAS	   Inclusion	  Criteria	   Exclusion	  Criteria	  
EMMA	  	  
1998	   49	  
Unilateral	  ≥75%	  
without	  thrombosis	  
or	  ≥60%	  with	  
positive	  
lateralization	  test*	  
-­‐	  DBP	  >95	  mmHg	  	  
-­‐	  GFR	  ≥50	  ml/min	  
-­‐	  malignant	  hypertension	  
-­‐	  stroke	  or	  AMI	  in	  previous	  6	  months	  	  
	  -­‐	  pulmonary	  edema	  
-­‐	  DBP	  >109	  mmHg	  at	  end	  of	  run-­‐in	  
SNRASCG	  	  
1998	   55	  
Uni-­‐	  or	  bilateral	  
≥50%	  
-­‐	  DBP	  >95	  mmHg	  with	  
at	  least	  2	  drugs	  
-­‐	  SCr	  >500	  µmol/L	  
-­‐	  stroke	  or	  AMI	  in	  previous	  3	  months	  
DRASTIC	  	  
2000	   106	  
Uni-­‐	  or	  bilateral	  
≥50%	  
-­‐	  DBP	  >95	  mmHg	  with	  
at	  least	  2	  drugs	  
-­‐	  SCr>200	  µmol/L	  
-­‐	  cancer	  
-­‐	  other	  forms	  of	  secondary	  hypertension	  
-­‐	  HF	  or	  unstable	  angina	  	  
-­‐	  single	  kidney	  with	  SCr	  >150	  µmol/L	  	  
-­‐	  stenotic	  kidney	  <8	  cm	  
-­‐	  renal	  artery	  occlusion	  	  
-­‐	  aortic	  aneurism	  needing	  surgery	  
STAR	  	  
2009	   140	  
Uni-­‐	  or	  bilateral	  
≥50%	  
-­‐	  GFR	  (Cockcroft	  Gault)	  
<80	  ml/min	  
-­‐	  stenotic	  kidney	  <8	  cm	  
-­‐	  renal	  artery	  <4	  mm	  
-­‐	  GFR	  <15	  ml/min	  
-­‐	  diabetes	  with	  proteinuria	  >3	  g/die	  
-­‐	  malignant	  hypertension	  
ASTRAL	  	  
2009	   806	  
Uni-­‐	  or	  bilateral	  
‘substantial	  
anatomical	  stenosis’	  
‘if	  the	  patient’s	  doctor	  
was	  uncertain	  
that	  the	  patient	  would	  
definitely	  have	  a	  
worthwhile	  
clinical	  benefit	  from	  
revascularization’	  
-­‐	  need	  of	  surgery	  or	  high	  revascularization	  
probability	  in	  6	  months	  
-­‐	  non	  atherosclerotic	  cardiac	  disease	  
-­‐	  previous	  renal	  revascularization	  
CORAL	  	  
2013	   947	  
Uni-­‐	  or	  bilateral	  
with:	  




-­‐	  if	  ≥80%	  (no	  
pressure	  gradient	  
required)	  
SBP	  ≥155	  mmHg	  on	  ≥2	  
drugs	  
-­‐	  DBP	  ≥120	  mmHg	  and/or	  SBP	  ≥200	  mmHg	  
-­‐	  stroke	  or	  TIA	  within	  3	  months	  or	  known	  
carotid	  stenosis	  ≥70%	  
-­‐	  major	  surgery,	  trauma,	  revascularization	  
procedure,	  unstable	  angina,	  or	  AMI	  in	  
previous	  30	  days	  	  
-­‐	  hospitalization	  for	  HF	  within	  3	  months	  
-­‐	  ejection	  fraction	  <30%	  
-­‐	  diabetes	  with	  either:	  
a.	  proliferative	  retinopathy	  and	  ≥1+	  protein	  
on	  urine	  dipstick,	  or	  
b.	  ≥1+	  protein	  on	  urine	  dipstick	  and	  urine	  
protein/Cr	  ratio	  >0.5	  
-­‐	  kidney	  size	  <8	  cm	  	  
-­‐	  SCr	  >3.0	  mg/dl	  
-­‐	  aneurysm	  of	  the	  abdominal	  aorta	  >4.0	  cm	  
-­‐	  previous	  renal	  artery	  bypass	  surgery	  or	  
angioplasty	  or	  stent	  intervention	  or	  kidney	  
transplant	  
-­‐	  intolerance	  to	  iodinated	  contrast,	  statin	  
or	  antiplatelets	  
*venouspielography,	  renal	  scintigraphy,	  renal	  venous	  renin	  concentration;	  ABPM=ambulatory	  BP	  monitoring;	  
AMI=acute	  myocardial	  infarction;	  BP=blood	  pressure;	  CKF=chronic	  kidney	  failure;	  DBP=diastolic	  BP;	  DDD=defined	  
daily	  dose;	  GFR=glomerular	  filtration	  rate;	  HF=	  heart	  failure;	  OBP=official	  BP;	  SCr=serum	  creatinine;	  n.a.=not	  
available.	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Table	  5:	  Randomized	  clinical	  trials	  characteristics:	  endpoints,	  follow-­‐up	  timing	  and	  types	  of	  analysis45	  
Study	  














EMMA	   -­‐	  BP	  by	  means	  of	  ABPM	  
No	  difference	  in	  BP	  
and	  creatinine	  
clearance.	  
DDD:	  1.78	  in	  Med	  vs.	  
1.0	  in	  PTRA	  group	  
(P=0.009)	  
6	   no	   7	  (27%)	   8.7	   0	  
SNRASCG	   -­‐	  OBP	  -­‐	  SCr	  
No	  BP	  difference	  in	  
unilateral	  ARAS.	  
Lower	  BP	  in	  bilateral	  
ARAS:	  171/91	  in	  Med	  
vs.	  152/83	  in	  PTRA	  
(P<0.01)	  
12	   no	   0	   0	   50.9	  
DRASTIC	   -­‐	  OBP	  
No	  difference	  in	  BP	  
at	  
3	  and	  12	  months.	  
N°	  drugs:	  2.4	  in	  Med	  
vs.	  1.9	  in	  PTRA	  group	  
(P<0.01)	  
12	   yes	   22	  (44%)	   3.6	   22.6	  
STAR	   -­‐	  GFR	  increase	  ≥20%	  
No	  difference	  in	  
rates	  of	  developing	  a	  
fall	  in	  GFR	  	  
24	   yes	   1	  (1.3%)	   71.8	   48	  
ASTRAL	  
-­‐	  mean	  slope	  of	  
the	  reciprocal	  of	  
serum	  SCr	  over	  
time	  
No	  difference	  in	  BP,	  
serum	  creatinine,	  
mortality,	  CHF	  at	  33	  
months	  (median)	  


















difference	  in	  regards	  
to	  the	  composite	  
endpoint,	  any	  of	  the	  
individual	  




SBP	  favoring	  the	  
PTRA	  group	  (−2.3	  
mmHg	  P=0.03)	  
60	   yes	   19	  (4%)	   100	   20	  
ABPM=ambulatory	  BP	  monitoring;	  AMI=acute	  myocardial	  infarction;	  BP=blood	  pressure;	  CKF=chronic	  kidney	  
failure;	  DBP=diastolic	  BP;	  GFR=glomerular	  filtration	  rate;	  HF=heart	  failure;	  OBO=official	  BP;	  SBP=systolic	  BP;	  SCr	  =	  
serum	  creatinine;	  n.a.	  =not	  available.	  In	  underlined	  the	  significant	  differences	  between	  groups.	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Meta-­‐analysis	  
Meta-­‐analysis	   published	   to	   date	   including	   CORAL	   trial45-­‐49,	   reported	   that	   the	   available	   data	   are	  
insufficient	  to	  conclude	  that	  revascularization	  in	  the	  form	  of	  balloon	  angioplasty,	  with	  or	  without	  
stenting,	  is	  superior	  to	  medical	  therapy	  for	  the	  treatment	  of	  ARAS.	  	  However,	  PTRAS	  does	  seem	  to	  
have	  a	  small	  drug-­‐saving	  effect	  and	  may	  result	  in	  a	  small	  improvement	  in	  diastolic	  BP.	  	  The	  clinical	  
importance	  of	  these	  benefits	  is	  unclear	  as	  there	  is	  no	  evidence	  that	  these	  improvements	  translate	  
into	   improved	   cardiovascular	   and	   renal	   outcomes.	   	   Therefore,	   balloon	   angioplasty	   appears	   safe	  
and	   results	   in	   similar	  numbers	  of	   cardiovascular	   and	   renal	   adverse	  events	   compared	   to	  medical	  
therapy.	  
There	  remains	  a	  need	  for	  further	  identification	  of	  subjects	  and	  appropriate	  indications	  in	  hopes	  of	  
improving	  outcomes	  and	  avoiding	  unnecessary	  procedures	  in	  patients	  who	  would	  not	  benefit	  from	  
treatment.	  
The	   Cochrane’s	   authors	   concluded	   that:	   “Further	   well-­‐conducted	   randomized	   controlled	   trials	  
comparing	  the	  effect	  of	  medical	  therapy	  and	  balloon	  angioplasty	   in	  patients	  with	  atherosclerotic	  
renal	   artery	   stenosis	   should	   be	   performed	   to	   overcome	   methodological	   errors	   evident	   in	   the	  
published	  literature.	  	  These	  trials	  should	  ensure	  a	  sufficient	  number	  of	  participants	  are	  included	  to	  
provide	   statistical	   power,	   unambiguous	   participant	   selection	   criteria,	   blinded	   outcome	  
assessment,	  and	  follow-­‐up	  of	  three	  or	  more	  years	  in	  order	  to	  evaluate	  the	  long-­‐term	  effect	  of	  the	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MATERIALS	  AND	  METHODS	  
METRAS	  study	  design	  
The	   decision	   to	   revascularize	   renal	   arteries	   in	   ARAS	   usually	   is	   based	   on	   the	   assumption	   that	  
ischemia	   is	   partially	   responsible	   for	   the	   decrease	   in	   kidney	   function	   and	   that	   correcting	   the	  
stenosis	  and	  restoring	  kidney	  perfusion	  will	  stabilize	  or	  improve	  glomerular	  filtration.	  	  The	  ultimate	  
aim	  of	   the	   treatment	   is	   to	  avoid	  or	  at	   least	  delay	   the	  need	   for	   renal	   replacement	   therapy.	   	  The	  
results	   of	   published	  RCTs37,39	   discouraged	  physicians	   to	  perform	  PTRAS	  except	   for	   patients	  with	  
compelling	  indications	  to	  treatment,	  as	  indicated	  in	  ACC/AHA	  guidelines26.	  
The	  primary	  objective	  of	  METRAS	  was	  to	  evaluate	  the	  GFR	  modification	  after	  PTRAS	  compared	  to	  
medical	  therapy	  in	  order	  to	  increase	  the	  knowledge	  on	  blocking	  or	  delaying	  ischemic	  nephropathy.	  
The	   trial	   protocol	   has	   been	   published49	   and	   is	   available	   online	  
(https://clinicaltrials.gov/ct2/show/NCT01208714).	  
1. OBJECTIVES	  
The	  primary	  objective	  of	  the	  METRAS	  study	  is	  to	  determine	  if	  PTRAS	  is	  superior	  or	  equivalent	  to	  
optimal	  medical	  treatment	  for	  preserving	  GFR	  in	  the	  ischemic	  kidney.	  
Secondary	  objectives	  are	  to	  determine	  if	  the	  two	  treatments	  are	  equivalent	  in:	  
1)	  lowering	  BP;	  	  
2)	   preserving	   overall	   renal	   function,	   as	   assessed	   by	   global	   estimated	  GFR	   and	   the	   reciprocal	   of	  
serum	  creatinine,	  and	  indexes	  of	  Ca2+	  and	  PO43-­‐	  metabolism;	  	  
3)	   decreasing	   the	   damage	   in	   target	   organs	   of	   hypertension,	   including	   cardiac	   hypertrophy,	  
microalbuminuria,	  and	  aortic	  stiffness;	  	  
4)	  improving	  quality	  of	  life.	  
2. STUDY	  DESIGN	  	  
METRAS	  Study	  is	  a	  prospective	  multicenter	  randomized,	  unblinded	  two-­‐arm	  study.	  	  
a. Enrolment.	  	  
Hypertensive	   patients	   of	   both	   genders	   (age	   >18	   years)	   were	   eligible	   if	   they	   had	   radiological	  
evidence	   of	   unilateral	   or	   bilateral	   RAS.	   	   Patients	   with	   clinical	   evidence	   suggestive	   of	   RAS	  
underwent	  angio-­‐CT	   to	   identify	  RAS.	   	  Clinical	  evidence	  of	  RAS	  was	  defined	  as	  unexplained	   renal	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dysfunction	   (GFR	   <60	   ml/min)50,	   uncontrolled	   or	   refractory	   hypertension,	   and/or	   significant	  
worsening	  of	  renal	  function	  (defined	  as	  20%	  increase	  of	  serum	  creatinine)	  after	  administration	  of	  a	  
renin-­‐angiotensin	   system	   blockers	   (ACE	   inhibitors	   or	   ARBs),	   and/or	   an	   abdominal	   bruit,	   and/or	  
evidence	  of	  atherosclerotic	  involvement	  of	  other	  sites.	  	  Eligible	  subjects	  were	  offered	  enrolment	  in	  
the	  study	  and	  must	  sign	  a	  written	  consent.	  
b. Inclusion	  Criteria	  
Patients	   were	   recruited	   if	   they	   had	   RAS	   determining	   an	   area	   stenosis	   of	   the	  main	   renal	   artery	  
lumen	   or	   its	   major	   branches	   either	   ≥70%	   or,	   if	   <70,	   with	   post-­‐stenotic	   dilatation	   at	   angio-­‐CT.	  	  
Fulfillment	  of	  these	  criteria	  will	  be	  assessed	  at	  the	  core	  laboratory	  of	  the	  coordinating	  center.	  
c. Exclusion	  Criteria	  	  
Exclusion	  criteria	  were:	  
1)	   detection	   of	   non-­‐significant	   acceleration	   (PSV	   <1.8	  m/sec)	   in	   renal	   arteries	   and	   homogeneity	  
between	   the	   Doppler	   resistance	   indexes	   of	   the	   upper,	   medium,	   and	   lower	   interlobar	   arteries	  
(when	   clearly	   visualized)	   or	   evidence	   of	   ischemic	   kidney	   diameter	   <10	   cm,	   and/or	   differences	  
between	  kidney	  diameters	  >20%,	  
2)	  compelling	  indication	  to	  PTRAS,	  for	  example,	  sub-­‐occlusive	  stenosis	  of	  the	  renal	  artery	  (>95%)	  
and/or	  rapidly	  worsening	  renal	  function,	  
3)	  refusal	  to	  participate	  in	  the	  study,	  	  
4)	  previous	  endovascular	  or	  surgical	  treatment	  of	  RAS,	  	  
5)	  fibromuscular	  RAS,	  	  
6)	  planned	  or	  ongoing	  pregnancy,	  or	  childbearing	  potential	  without	  adequate	  measures	  to	  prevent	  
pregnancy,	  	  
7)	  life	  expectancy	  <2	  years,	  	  
8)	  current	  participation	  to	  another	   trial	  possibly	   influencing	   the	  safety	  of	   the	  patient	  and/or	   the	  
outcomes	  of	  the	  study,	  	  
9)	  co-­‐morbid	  conditions	  or	  any	  other	  circumstances	  likely	  to	  limit	  participation	  and	  availability	  to	  
long-­‐term	  follow-­‐up	  studies.	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d. Run-­‐in	  period	  
Eligible	  patients	  underwent	  a	  4-­‐8	  weeks	  run-­‐in	  period	  during	  which	  BP	  treatment	  was	  optimized,	  
LDL-­‐cholesterol	   was	   lowered	   to	   below	   2.17	   mmol/L	   (80	   mg/dL),	   homocysteine	   if	   elevated	   was	  
lowered	  possibly	   to	   less	   than	  15	  μmol/L	   (with	   folate	  and	  vitamin	  B6/B12	  supplementation),	  and	  
treatment	  for	  diabetes	  was	  optimized	  to	  achieve,	  if	  feasible,	  a	  HbA1c	  <6.5%	  (Fig	  7).	  
As	   these	  patients	  are	   to	  be	  considered	  at	  high-­‐risk	  anti-­‐hypertensive	   treatment	  was	  adjusted	   to	  
attain	   a	   BP	   <130/85	  mmHg.	   	   However,	   due	   to	   vascular	   remodeling	   this	   target	   BP	   value	  will	   be	  
difficult	  to	  reach	  in	  these	  patients51,	  therefore,	  a	  target	  BP	  level	  <140/90	  mmHg	  was	  acceptable.	  	  
All	   classes	   of	   antihypertensive	   drugs	   were	   allowed	   paying	   utmost	   attention	   to	   the	   changes	   in	  
serum	  creatinine	  during	  treatment,	  particularly	  if	  ACE-­‐inhibitors	  and	  ARB	  were	  needed.	  	  Full	  doses	  
of	   antihypertensive	  medications,	   including	   a	   diuretic,	   were	   expected	   to	   allow	  most	   patients	   to	  
reach	  the	  target	  value.	  
Statins	  and/or	  ezetimibe	  (in	  patients	  with	  history	  of	  rabdomyolysis	  with	  statins)	  were	  titrated	  to	  
achieve	   a	   LDL-­‐cholesterol	   <2.07	   mmol/L	   (80	   mg/dl).	   	   Treatment	   with	   oral	   antidiabetic	   agents	  
and/or	   insulin	  was	  adjusted	  to	  reach	  post-­‐prandial	  glycaemia	  <11	  mmol/L.	   	  All	  patients	   received	  
antiplatelet	  treatment	  with	  the	  same	  dose	  of	  aspirin	  (100	  mg	  o.d.)	  or	  clopidogrel	  (75	  mg	  o.d.),	  or,	  
if	   intolerant	   to	   ASA	   and	   clopidogrel,	   ticlopidine	   (250	   mg	   b.i.d),	   throughout	   the	   study	   period.	  	  
Cessation	  of	  smoking	  was	  strongly	  recommended.	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Fig.	  7.	  Study	  design	  
	  
	  
e. Imaging	  and	  renal	  function.	  	  	  
Angio-­‐CT	  was	  performed	  to	  assess	  the	  abdominal	  aorta	  and	  renal	  arteries	  anatomy	  and	  pathology.	  
The	  evaluation	  of	  grade	  of	  stenosis	  was	  performed	  by	  means	  of	  the	  assessment	  of	  cross	  sectional	  
area	   with	   a	   specific	   software	   (Vessel	   analysis,	   Syngo	   Siemens,	   Erlangen,	   Germany).	   	   Utmost	  
precautions	  were	   adopted	   to	  minimize	   the	   chances	   of	   worsening	   renal	   function	  with	   angio-­‐CT.	  	  
The	   site	   of	   the	  RAS	  was	   assessed	  by	   two	  experienced	   radiologists.	   	   Post-­‐stenotic	   dilatation	  was	  
also	  determined	  and	  taken	  as	  a	  surrogate	  marker	  of	  hemodynamically	  relevant	  RAS	  whenever	  the	  
luminal	  narrowing	  was	  <70%	  at	  biplane	  angiography.	  	  
When	  more	   renal	   arteries	  were	   detected,	   the	   patient	  was	   enrolled	   if	   a	   stenosis	   ≥70%	   or	   post-­‐
stenotic	  dilatation	  was	  found	  in	  the	  largest	  artery.	  
All	  on-­‐site	  measurements	  from	  imaging	  were	  validated	  by	  the	  core	  laboratory	  in	  Padova.	  
	   25	  
f. Assessment	  of	  kidney	  perfusion.	  	  	  
99mTc-­‐DTPA	   renal	   scintigraphy	  was	  performed	  on	  2	   consecutive	   days,	   before	   and	   after	   captopril	  
administration,	   according	   to	   guidelines	   (http://interactive.snm.org/docs/pg_ch16_0403.pdf).	   	   If	  
serum	  creatinine	   level	  after	  angio-­‐CT	  did	  not	  differ	   significantly	   from	  that	  measured	  before,	   the	  
patient	   discontinued	   ACEI	   and/or	   ARBs	   for	   1	   week	   and	   then	   underwent	   99mTc-­‐DTPA	   sequential	  
renal	   scintigraphy.	   	   If	   an	   increase	   in	   serum	   creatinine	   levels	   >20%	   from	  baseline	   occurred	   after	  
angioCT,	  scintigraphy	  was	  delayed	  until	  full	  restoration	  of	  renal	  function.	  
The	  captopril	  dose	  (50	  mg	  per	  os)	  was	  given	  60	  min	  before	   injection	  of	  99mTc-­‐DTPA	  (3.7	  MBq/kg	  
body	  weight)	   and	   a	   similar	   dose	  was	   injected	   for	   the	   basal	   study,	   at	   least	   after	   24	   h.	   	   BP	  was	  
checked	   every	   15	   min	   after	   captopril	   administration.	   	   Before	   the	   scintigraphy	   ACEI/ARB	   were	  
stopped	   for	   3-­‐7	   days	   (depending	   on	   drug	   half-­‐life);	   if	  withdrawal	  was	   judged	   to	   be	   unsafe,	   the	  
captopril	  scintigraphy	  was	  omitted	  and	  only	  baseline	  99mTc-­‐DTPA	  scintigraphy	  was	  performed.	  
Scintigraphy	   data	   analysis	   and	   split	   GFR	   were	   calculated	   with	   a	   specific	   software	   on	   a	   nuclear	  
medicine	  workstation.	   	   The	   captopril	   scintigraphy	  was	   considered	   positive	  when	   a	   reduction	   of	  
10%	  or	  more	  in	  split	  renal	  function	  was	  observed.	  	  All	  scintiscan	  data	  were	  evaluated	  and	  validated	  
at	  the	  core	  laboratory	  in	  Padova.	  
g. Assessment	  of	  renal	  function.	  	  	  
Global	  renal	  function	  was	  assessed	  by	  means	  of	  glomerular	  filtration	  rate	  (GFR)	  using	  the	  CKD-­‐EPI	  
formula50,	   and	   by	   urinalysis,	   and	   measurement	   of	   serum	   (S)-­‐erythropoietin,	   S-­‐electrolytes,	   S-­‐
creatinine,	  S-­‐urea,	  S-­‐homocysteine,	  cystatin	  C,	  uric	  acid,	  PTH,	  PTH-­‐related	  peptide	  (PTHr),	  25-­‐OH	  
and	  1-­‐25-­‐OH	  vitamin	  D.	  
h. Assessment	  of	  target	  organ	  damage	  (TOD).	  	  
Besides	  the	  anthropometric	  and	  clinical	  data,	  total	  serum	  homocysteine,	  glycosylated	  hemoglobin,	  
lipids	   (total	   cholesterol,	   HDL-­‐	   and	   LDL-­‐cholesterol,	   triglycerides)	  were	   determined	   as	   indexes	   of	  
metabolic	  risk.	   	  Transthoracic	  echocardiogram	  with	  Doppler	  to	  assess	   left	  ventricular	  mass	   index	  
(LVMI),	  relative	  wall	  thickness	  (h/r),	  the	  E/A	  wave	  peak	  flow	  velocity	  rate	  and	  tissue	  Doppler	  were	  
used	   to	  detect	   changes	   in	   LV	   remodeling	  and	  diastolic	   filling	   changes52-­‐53.	   	   Left	   ventricular	  mass	  
was	  calculated	  by	  means	  of	  the	  Devereux’s	  formula54	  normalized	  for	  BSA	  and	  height.	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i. Assessment	  of	  blood	  pressure.	  	  	  
Clinic	   and	  24	  hours	  ambulatory	  blood	  pressure	  monitoring	   (ABPM)	  were	  performed	   to	  evaluate	  
the	  changes	  of	  BP	  values	  in	  each	  treatment	  arm.	  	  	  
j. Randomization.	  	  
The	   patients	   were	   randomly	   assigned	   to	   either	   PTRAS	   on	   top	   of	   optimal	   medical	   therapy	  
(revascularization	  arm)	  or	  to	  optimal	  medical	  therapy	  alone	  (medical	  therapy	  arm)	  by	  means	  of	  an	  
algorithm	  at	   the	   core	   laboratory	   (see	   later).	   	   Because	   the	  number	  of	   the	  patients	  with	  bilateral	  
stenosis	   was	   smaller	   than	   that	   with	   unilateral	   stenosis,	   the	   algorithm	   considered	  
unilateral/bilateral	  stenosis	  to	  achieve	  an	  equal	  number	  of	  patients	  in	  each	  treatment	  arm	  (Fig.	  8)	  
	  
Revascularization 







Time (mo) 1 0 1 3 6 12 18 24 30 36 42 48 54 60 
t-1 t0 t1 t2 t3 t4 t5 t6 t7 T8 T9 t10 T11 t12 
Clinical evaluation x x x x x x x x x x x x x x 
Lab tests x x x x x x x x x x 
Scintiscan x x x x x x x 
Renal echoDoppler x x x x x x x x 
AngioTC x x x 
Echocardiography x x x x x x x 
ABPM x x x x x x x x x 
Studio METRAS: flow chart 
Run-in Randomization 
	  
Fig.	  8.	  Flow-­‐chart	  
	  
k. Treatment	  arms	  
Revascularization.	   In	   the	  patients	   randomized	   to	  PTRAS	   lesions	   involving	   the	  ostium	  and/or	   the	  
main	  renal	  artery	  were	  treated;	  more	  distal	  stenoses	  were	  recorded	  for	  data	  analysis	  purposes	  but	  
not	  treated.	   	  A	  balloon-­‐expandable	  stent	  (Palmaz	  Genesis	  on	  Cordis	  AMIIA	  Delivery	  System)	  was	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implanted	   during	   PTRA.	   After	   PTRAS	   the	   patients	   continued	   on	   their	   antihypertensive	   drug	  
regimen.	   	  The	  dose	  and	  number	  of	  drugs	  were	  down-­‐titrated,	   if	  necessary,	   to	   reach	  a	   target	  BP	  
values	  <130/80	  mmHg	  for	  systolic	  and	  diastolic.	  
Medical	   therapy.	   The	   patients	   randomized	   to	   medical	   treatment	   were	   continued	   on	   the	   drug	  
regimen	   optimized	   during	   the	   run-­‐in	   period.	   	   Adjustment	   of	   antihypertensive	   drug	   therapy	  
allowed	  to	  achieve	   the	  best	  possible	  control	  of	  BP;	  changes	  of	   treatment	   (number	  and	  doses	  of	  
each	  drug)	  were	  recorded	  for	  the	  purpose	  of	  data	  analysis.	  
l. Follow-­‐up.	  	  
Visits	  were	  scheduled	  at	  1	  (t1),	  3	  (t2),	  6	  (t3),	  12	  (t4)	  and	  24	  (t5)	  months	  after	  revascularization	  or	  
beginning	  of	  the	  medical	  therapy	  (t0).	  	  The	  study	  then	  continued	  in	  an	  observational	  setting	  with	  
outpatient	  visits	  scheduled	  at	  1	  year	  intervals	  for	  a	  total	  of	  5	  years.	  	  
m. 	  Duration	  of	  the	  Study	  
The	  METRAS	  Study	  will	   last	  for	  5	  years.	  	  This	  time	  interval	  is	  expected	  to	  be	  sufficient	  to	  register	  
renal	  and	  major	  cardiovascular	  events.	  	  
3. EXPERIMENTAL	  ENDPOINTS	  
The	  GFR	  value	  assessed	  by	  99mTc-­‐DTPA	  in	  the	  ischemic	  kidney	  was	  used	  as	  a	  quantitative	  variable	  
and	   compared	   between	   groups	   at	   each	   time	   point	   during	   follow-­‐up.	   	   For	   the	   purpose	   of	   Cox	  
regression	  analysis	   a	   categorical	   definition	  of	   kidney	   loss,	   defined	  as	   fall	   of	  GFR	  of	   the	   ischemic	  
kidney	  to	  <5	  ml/min,	  was	  used;	  rate	  of	  achievement	  of	  such	  endpoint	  were	  compared.	  
4. HANDLING	  OF	  POTENTIAL	  CONFOUNDERS	  
To	  minimize	   the	  untoward	  effect	   of	   differences	   in	  CV	   risk	  management,	   all	   patients	  were	   given	  
anti-­‐platelet,	   lipid-­‐lowering,	   and	   anti-­‐diabetic	   agents	   if	   needed.	   	   These	   treatments	   were	   up-­‐
titrated	  to	  reach	  the	  desired	  effect	  or	  to	  the	  daily	  defined	  dose	  (DDD)55	   if	   tolerated.	   	  They	  were	  
thereafter	  maintained	  at	  the	  dose	  achieved	  at	  the	  end	  of	  the	  run-­‐in	  period	  throughout	  the	  study,	  
unless	  otherwise	  indicated.	  	  
5. DATA	  COLLECTION	  and	  STATISTICAL	  ANALYSIS	  
Data	   were	   collected	   using	   specifically	   predefined	   forms	   in	   an	   ad	   hoc	   designed	   database.	   	   The	  
building	  up	  of	  the	  database	  was	  monitored	  in	  real	  time	  at	  the	  core	  laboratory.	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Power	  calculations.	  
Power	  calculation	  (nQuery	  Vers,	  6.0,	  Statistical	  Solutions)	  showed	  that	  assuming	  a	  16%	  drop-­‐out	  
rate,	   a	   common	   GFR	   standard	   deviation	   (SD)	   of	   8.0	   ml/min,	   an	   equal	   sample	   size	   in	   each	  
treatment	  arm,	  using	  a	  two	  group	  t-­‐test	  with	  a	  0.05	  2-­‐sided	  significance	  level,	  with	  60	  patients	  per	  
arm	  our	  study	  will	  have	  a	  99%	  power	  to	  detect	  a	  difference	  in	  means	  of	  GFR	  in	  the	  vascularized	  (or	  
control	  untreated	  kidney)	  of	  7.5	  ml/min.	  
To	   obtain	   homogeneous	   distribution	   of	   characteristics	   of	   patients	   between	   arms,	   we	   used	   the	  
Treatment	   Allocation	   Procedure	   for	   Sequential	   Clinical	   Trial56.	   The	   allocation	   was	   performed	  
considering	  baseline	  total	  GFR	  at	  NAFS,	  presence	  of	  diabetes	  mellitus,	  stenosis	  <70	  or	  >=70%,	  age	  
<68	  or	  >=68	  years,	  and	  gender.	  
Continuous	   variables	   are	   expressed	   as	  means	   and	   SD	   and	   were	   compared	   at	   Student’s	   t-­‐tests.	  
Comparison	  of	  GFR	  by	  NAFS	  in	  the	  ischemic	  kidney	  between	  groups	  (revascularization	  vs.	  medical	  
therapy)	  at	  each	  time	  point	  was	  performed	  using	  Student’s	  t-­‐test,	  repeated	  measures	  ANOVA	  with	  
adjustment	  of	  potential	  confounders,	  and	  a	  repeated	  measures	  generalized	  linear	  model	  analysis	  
(GLM),	  Method	  A.	   	  GFR	   in	   ischemic	  kidney	  was	  also	  derived	  from	  eGFR	  (with	  CKD-­‐EPI	   formula50)	  
multiplied	  for	  percentage	  of	  filtration	  assessed	  by	  NAFS,	  obtaining	  new	  GFR	  in	  ischemic	  kidney	  at	  
each	  time-­‐point	  (Method	  B).	  	  
We	   used	  mean	   substitution	   to	   replace	  missing	   values	   at	   each	   time-­‐points,	   because	   not	   all	   the	  
patients	  completed	  the	  follow-­‐up.	  
All	  analyses	  were	  performed	  with	  the	  use	  of	  SPSS	  software,	  (IBM).	  
5. EXPECTED	  RESULTS.	  	  
With	  its	  high	  power	  this	  study	  should	  clarify	  whether	  PTRAS	  on	  top	  of	  optimal	  medical	  therapy	  is	  
superior	   or	   equivalent	   to	   the	   latter	   alone	   in	   preventing	   deterioration	   of	   GFR	   in	   the	   ischemic	  
kidney.	   	   Assessment	   of	   secondary	   endpoints	   will	   elucidate	   some	   clinically	   relevant	   issues	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RESULTS	  
Patients	  
From	   June	  2010	   through	  April	  2015,	   thirty	  patients	  were	  evaluated	   for	   inclusion	   in	   the	  METRAS	  
trial	  at	  Hypertension	  Clinic	  in-­‐patient	  or	  out-­‐patient	  facilities,	  Centre	  of	  Excellence	  of	  the	  European	  
Society	  of	  Hypertension,	  Department	  of	  Medicine,	  University	  of	  Padua.	  	  Ten	  of	  these	  patients	  did	  
not	  meet	  the	  inclusion	  criteria	  and	  therefore	  were	  excluded:	  six	  for	  compelling	  indication	  to	  PTRAS	  
according	  to	  the	  AHA/ACC	  guidelines26	  (for	  sub-­‐occlusive	  renal	  artery	  stenosis	  with	  rapid	  declining	  
renal	   function),	   two	   for	  non-­‐significant	  stenosis,	  one	   for	   fibromuscular	  dysplasia;	  one	  refused	  to	  
participate	  to	  the	  study.	  	  
During	  the	  study,	  two	  additional	  patients	  were	  excluded	  for	  lack	  of	  adherence	  to	  the	  protocol	  as	  
they	  failed	  to	  attend	  the	  regular	  outpatient	  visits	  and	  follow-­‐up	  exams.	  	  
Up	   to	   April	   2015,	   eighteen	   patients	   were	   enrolled,	   ten	   in	   the	   endovascular	   and	   eight	   in	   the	  
medical	  treatment	  arm	  (Fig.	  9).	  	  All	  the	  patients	  had	  unilateral	  stenosis	  with	  a	  mean	  percentage	  of	  
stenosis	  of	  76%	  in	  both	  groups.	  	  90%	  of	  patients	  had	  a	  cross	  sectional	  area	  stenosis	  >70%.	  	  The	  two	  
patients	  with	  stenosis	  <70%	  had	  also	  a	  post-­‐stenotic	  dilation,	  which	  according	  to	  the	  protocol	  was	  
held	  to	  indicate	  a	  hemodynamically	  significant	  stenosis.	  
No	  crossover	  of	  patients	  from	  one	  to	  the	  other	  treatment	  arm	  occurred.	  
The	   baseline	   features	   of	   the	   patients	   assigned	   to	   the	   PTRAS	   and	   the	  medical	   therapy	   arms	   are	  
shown	  in	  the	  table	  6.	  	  The	  mean	  age	  of	  the	  cohort	  was	  68±9	  years,	  there	  was	  a	  trend	  toward	  more	  
females	  and	  diabetics	  in	  the	  PTRAS	  group,	  but	  the	  difference	  was	  not	  significant.	  
Mean	  24	  hours	  BP	  was	  138/73	  mmHg	   in	  the	  medical	   treatment	  group	  and	  131/70	  mmHg	   in	  the	  
endovascular	  group	  with	  a	  mean	  number	  of	  drugs	  of	  3.6	  and	  3.1,	  respectively.	  
Renal	   function	   did	   not	   differ	   between	   groups	   assessed	   by	  NAFS	   in	   terms	   of	   total	   GFR	   and	  GFR	  
measured	   separately	   in	   two	  kidneys	  nor	  by	  bioumoral	  parameters	   (GFR	  estimated	  with	  CKD-­‐EPI	  
formula,	  serum	  creatinine	  and	  cystatin-­‐c).	  
Left	  ventricular	  mass	  assessed	  at	  echocardiography	  was	  similar	  in	  the	  two	  arms.	  
None	  of	  the	  baseline	  characteristics	  differed	  between	  the	  two	  groups.	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Fig.	  9.	  Screening,	  Randomization,	  and	  Follow-­‐up.	  
At	  completion	  of	  my	  PhD	  course	  the	  median	  follow-­‐up,	  which	  is	  still	  ongoing,	  was	  36	  months.	  
In	  the	  revascularization	  group	  all	  the	  patients	  underwent	  angiography	  plus	  stenting	  without	  major	  
complications.	  	  The	  success	  rate	  of	  the	  procedure	  was	  100%	  without	  residual	  stenosis.	  	  There	  was	  
an	   intra-­‐stent	   restenosis	   <50%	   at	   6	   month	   after	   PTRAS	   in	   1	   patient	   who	   did	   not	   require	   re-­‐
intervention	  for	  the	  stability	  of	  clinical,	  bioumoral,	  and	  scintigraphyc	  parameters.	  	  This	  patient	  got	  
closer	  follow-­‐up	  visits.	  	  
All	  the	  patients	  in	  both	  groups	  were	  treated	  with	  antiplatelets	  therapy	  according	  to	  the	  METRAS	  
protocol	   and	  with	   antihypertensive	   agents	   including	   an	   ACE-­‐I	   or	   ARB	   (except	   2	   in	   PTRAS	   group	  
under	  therapy	  with	  calcium	  channel	  blocker	  and/or	  beta-­‐blocker).	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Tab.	  	  6	  Baseline	  characteristics	  of	  population	  




Age	  (years)	   69±10	   67±8	  
Male/Female	  (%)	   4	  (50)	  /	  4	  (50)	   2	  (20)	  /	  8	  (80)	  
%	  of	  stenosis	   76±7.3	   76.1±7.6	  
Degree	  of	  Stenosis:	  (n.	  of	  patients	  and	  %)	  
<70%	   1	  (12.5)	   1	  (10)	  
70-­‐80%	   5	  (62.5)	   5	  (50)	  
>80%	   2	  (25)	   4	  (40)	  
Body	  Mass	  Index	  (Kg/m2)	   26.2±5.6	   24.9±3.5	  
Diabetes	  (%)	   1	  (12.5)	   3	  (30)	  
24	  hours	  SBP	  (mmHg)	   138±14	   131±14	  
24	  hours	  DBP	  (mmHg)	   73±8	   70±9	  
Number	  of	  Drugs	   3.6±1.5	   3.1±1.4	  
total	  GFR	  by	  NAFS	  (ml/min/m2)	   71.4±22.5	   80±21.2	  
GFR	  in	  ischemic	  kidney	  by	  NAFS	  
(ml/min/m2)	  
33.4±12.7	   29.7±10.4	  
GFR	  in	  contralateral	  kidney	  by	  NAFS	  
(ml/min/m2)	  
38±14.3	   50.3±19.2	  
Serum	  Creatinine	  (mcmol/L)	   83.7	  ±23	   70	  ±11	  
Serum	  Cystatin-­‐c	  (mg/L)	   0.90±0	   0.92±0.23	  
eGFR	  with	  CDK-­‐EPI	  (mg/ml/1,73m2)	   81.1±15.4	   88.2±15.1	  
Microalbuminuria	  
(mg/g	  creatinine)	  
33.7±35	   15.7±11	  
Glycosylated	  hemoglobin	  (mmol/mol)	   44.7±14.4	   43.1±6.7	  
Total	  Cholesterol	  (mmol/L)	   4.2±0.8	   4.7±1.3	  
HDL	  (mmol/L)	   1.2±0.3	   1.3±0.3	  
Triglycerides	  (mmol/L)	   1±0.3	   1.3±0.1	  
LDL	  (mmol/L)	   2.5±0.7	   2.9±1.1	  
Homocysteine	  (mcmol/L)	   17±6.1	   11.8±4.9	  
Left	   ventricular	   mass	   normalized	   for	   Body	  
Surface	  Area	  (g/m2)	  
114.7±16.7	   110±15.8	  
Left	  ventricular	  mass	  normalized	   for	  height	  
(g/m2.7)	  
52.2±7.7	   50.1±9.5	  
Relative	  Wall	  Thickness	   0.55±0.15	   0.49±0.07	  
Resistive	  index	  in	  ischemic	  kidney	  (%)	   71.4±9.4	   69.7±7.7	  
Resistive	  index	  in	  contralateral	  kidney	  (%)	   73.2±8.1	   75±4.6	  
None	  of	  variables	  differed	  between	  groups.	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PRIMARY	  ENDPOINT	  
GFR	  in	  the	  ischemic	  kidney	  assessed	  by	  NAFS:	  method	  A	  
At	   repeated	   measures	   generalized	   linear	   model	   analysis	   (GLM)	   that	   included	   age	   and	   DBP	   at	  
baseline	   as	   covariates,	   GFR	   in	   the	   ischemic	   kidney	   as	   assessed	   at	   NAFS	   increased	   compared	   to	  
medical	  treatment	  at	  3	  years	  follow-­‐up,	  albeit	  it	  was	  borderline	  significant	  (p=0.07).	  
GFR	  in	  the	  ischemic	  kidney	  assessed	  by	  NAFS:	  method	  B	  
At	   GLM	   that	   included	   age	   and	   DBP	   at	   baseline	   as	   covariates,	   GFR	   in	   the	   ischemic	   kidney	   as	  
assessed	  at	  NAFS	  increased	  compared	  to	  medical	  treatment	  at	  3	  years	  follow-­‐up	  (p=0.048).	  
GFR	  in	  the	  ischemic	  kidney	  assessed	  by	  NAFS	  excluding	  the	  3	  years	  time-­‐point:	  method	  B	  
We	  performed	   the	   previous	   analysis	   excluding	   the	   3	   years	   time-­‐point,	   in	  whom	   the	   number	   of	  
patients	  was	  too	  small.	   	  At	  GLM	  that	   included	  age	  and	  DBP	  at	  baseline	  as	  covariates,	  GFR	  in	  the	  
ischemic	  kidney	  as	  assessed	  at	  NAFS	  increased	  compared	  to	  medical	  treatment	  at	  3	  years	  follow-­‐
up	  (p=0.027)	  (Fig.	  10	  and	  Tab.	  7).	  
	  
	  








baseline 6 months 1 year 2 years 
p = 0.027 











Tab.	  7	  GFR	  in	  ischemic	  kidney	  from	  eGFR	  X	  %	  by	  NAFS	  (ml/min/1.73m2)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   35.4	   11.4	   35.5	   9.8	   35.9	   5.8	   30.0	   7.6	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GFR	  in	  the	  contralateral	  kidney	  assessed	  by	  NAFS:	  method	  A	  
At	   GLM	   including	   as	   covariates	   age	   and	   DBP	   at	   baseline,	   GFR	   in	   the	   contralateral	   kidney	   as	  
assessed	  at	  NAFS	  did	  not	  differ	  in	  the	  two	  groups	  at	  3	  years	  follow-­‐up	  (p=0.642).	  
GFR	  in	  the	  contralateral	  kidney	  assessed	  by	  NAFS:	  method	  B	  
At	   GLM	   including	   as	   covariates	   age	   and	   DBP	   at	   baseline,	   GFR	   in	   the	   contralateral	   kidney	   as	  









GFR IN CONTRALATERAL KIDNEY FROM eGFR X % BY NAFS 
baseline 6 months 1 year 2 years 3 years 











Tab.	  8	  GFR	  in	  contralateral	  kidney	  from	  eGFR	  X	  %	  by	  NAFS	  (ml/min/1.73m2)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   39.5	   10.8	   43.6	   11.1	   35.1	   3.5	   35.5	   7.0	   39.9	   4.9	  
PTRAS	   50.7	   9.1	   47.8	   15.7	   47.0	   11.0	   50.9	   7.5	   47.3	   2.6	  
	  
Fig.	  11	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Total	  GFR	  assessed	  by	  NAFS	  	  
At	  GLM	   including	   as	   covariates	   age	  and	  DBP	  at	  baseline,	   total	  GFR	  as	   assessed	  at	  NAFS	  did	  not	  









TOTAL GFR BY NAFS 






baseline 6 months 1 year 2 years 3 years 
	  
Tab.	  9	  Total	  GFR	  assessed	  by	  NAFS	  (ml/min/m2)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   71.4	   22.5	   69.6	   20.1	   69.2	   15.6	   73.7	   13.3	   69.7	   1.2	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SECONDARY	  ENDPOINTS	  
Blood	  pressure	  control:	  24	  hours	  Systolic	  Blood	  Pressure	  assessed	  by	  ABPM	  
At	  GLM	  including	  as	  covariates	  age,	  sex,	  and	  DBP	  at	  baseline,	  24	  hours	  SBP	  did	  not	  differ	  between	  









24 HOURS SYSTOLIC BP 



























Tab.	  10	  24	  hours	  SBP	  (mmHg)	  
	  
BASELINE	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   130.5	   14.5	   133.3	   7.7	   138.2	   10.6	   124.0	   5.3	   131.1	   6.4	   128.5	   5.2	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Blood	  pressure	  control:	  24	  hours	  Diastolic	  Blood	  Pressure	  assessed	  by	  ABPM	  
At	   GLM	   including	   as	   covariates	   age	   and	   DBP	   at	   baseline,	   24	   hours	   DBP	   diverged	   between	   the	  
PTRAS	  group	  and	  the	  medical	  therapy	  starting	  from	  6	  months	  post-­‐revascularization.	   	  At	  3	  years	  







24 HOURS DIASTOLIC BP 



























Tab.	  11	  24	  hours	  DBP	  (mmHg)	  
	  
BASELINE	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   68.7	   9.5	   71.8	   4.2	   75.3	   7.4	   72.2	   6.5	   72.5	   8.0	   69.6	   3.3	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Blood	  pressure	  control:	  number	  of	  drugs	  
At	  GLM	  including	  as	  covariates	  age	  and	  DBP	  at	  baseline,	  number	  of	  drugs	  decreased	  compared	  to	  
medical	   treatment	  at	  3	  years	   follow-­‐up,	  although	   it	  was	  borderline	   significant	   (p=0.055)	   (Fig.	  15	  
and	  Tab.	   12).	   	   The	  ANOVA	   test	   revealed	  a	  decreased	  number	  of	   drugs	   in	   the	  PTRAS	  group	  at	   3	  
months,	   1	   year,	   and	   2	   years	   compared	   to	   the	   medical	   therapy	   group	   (p=0.047	   at	   6	   months,	  

































p = 0.055 
	  
Tab.	  12	  Number	  of	  Drugs	  	  
	  
BASELINE	   1	  MONTH	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   3.6	   1.5	   3.7	   1.4	   3.8	   1.9	   4.0	   1.2	   4.0	   1.2	   4.4	   0.7	   4.5	   0.6	  
PTRAS	   3.1	   1.4	   2.8	   1.1	   2.5	   1.2	   2.5	   1.2	   2.8	   1.3	   2.3	   1.4	   2.4	   1.3	  
ANOVA	  (p)	   0.142	   0.144	   0.047	   0.094	   0.016	   0.048	   0.158	  
	  
Fig.	  15	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Renal	  function:	  estimated	  GFR	  by	  CKD-­‐EPI	  
At	  GLM	  including	  as	  covariates	  age,	  eGFR,	  and	  DBP	  at	  baseline,	  eGFR	  as	  assessed	  with	  CKD-­‐EPI	  did	  














































Tab.	  13	  estimated	  GFR	  by	  CKD-­‐EPI	  (mg/ml/1.732)	  
	  
BASELINE	   1	  MONTH	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   75	   15	   68.5	   10.9	   67	   9	   79.2	   19.1	   71	   3.5	   65.5	   10.2	   78	   3.2	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Renal	  function:	  serum	  creatinine	  
At	  GLM	  including	  as	  covariates	  age,	  DBP,	  and	  creatinine	  at	  baseline,	  serum	  creatinine	  was	  lower	  in	  









































Tab.	  14	  Serum	  creatinine	  (mcmol/L)	  
	  
BASELINE	   1	  MONTH	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   89.3	   29.4	   93.2	   12.8	   105.2	   22.1	   91	   23.6	   90.7	   8.2	   98.2	   15.4	   87	   7.6	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Renal	  function:	  cystatin-­‐c	  
At	  GLM	  including	  as	  covariates	  age	  DBP	  and	  cystatin-­‐c	  at	  baseline,	  serum	  cystatin-­‐c	  was	  lower	  in	  






























Tab.	  15	  Cystatin-­‐c	  (mg/L)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   0.8	   0.1	   0.9	   0.1	   0.8	   0.20	   0.9	   0.1	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Metabolic	  control:	  LDL	  
At	  GLM	  including	  as	  covariates	  age	  BMI	  and	  LDL	  at	  baseline,	  LDL	  did	  not	  differ	  in	  the	  two	  groups	  at	  





































Tab.	  16	  LDL-­‐cholesterol	  (mmol/L)	  
	  
BASELINE	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   2.1	   0.7	   2	   0.3	   2.4	   0.8	   1.9	   0.4	   1.9	   0.1	   1.9	   0.1	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Metabolic	  control:	  HBA1c	  
At	  GLM	  including	  as	  covariates	  age,	  presence	  of	  diabetes	  and	  HbA1c	  at	  baseline,	  HBA1c	  was	  lower	  




































Tab.	  17	  HBA1c	  (mmol/mol)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   47	   13.4	   47.3	   14.4	   53.5	   13.9	   50.7	   13.4	   47.7	   9	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Metabolic	  control:	  homocysteine	  
At	   GLM	   including	   as	   covariates	   age,	   BMI,	   and	   homocysteine	   at	   baseline,	   homocysteine	   did	   not	  


































Tab.	  18	  Homocysteine	  (mcmol/L)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   18.4	   5.1	   15.9	   3.6	   13.2	   3	   14.3	   4.7	   15.1	   3.6	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TARGET	  ORGAN	  DAMAGE	  
Kidney	  –	  Microalbuminuria	  
At	  GLM	  including	  as	  covariates	  age	  DBP	  and	  microalbuminuria	  at	  baseline,	  microalbuminuria	  was	  








































Tab.	  19	  Microalbuminuria	  (mg/g	  creatinine)	  
	  
BASELINE	   3	  MONTHS	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   24.7	   19.6	   15.7	   8.6	   14.2	   13.5	   41.9	   33.8	   84.6	   94.5	   25.2	   5.8	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Kidney	  –	  Resistive	  index	  assessed	  by	  Echo-­‐Doppler	  
At	  GLM	   including	  as	   covariates	  age	  and	  DBP	  at	  baseline,	   IR	   in	   ischemic	  kidney	  was	   lower	   in	   the	  
medical	   therapy	  compared	  to	  the	  PTRAS	  group,	  although	   it	  was	  borderline	  significant	   (p=0.052).	  	  


























p = 0.052 
	  
	  
Tab.	  20	  IR	  in	  ischemic	  kidney	  
	  
BASELINE	   1	  MONTH	   3	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   71.4	   8.7	   68	   8.9	   69.9	   7.9	   70.9	   5.3	   69	   8.4	  
PTRAS	   69.7	   7.3	   75.5	   7.5	   71.5	   5.7	   72.3	   6.3	   74	   4.2	  
	  
Fig.	  23	  

























p = NS 
	  
	  
Tab.	  21	  IR	  in	  contralateral	  kidney	  
	  
BASELINE	   1	  MONTH	   3	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  
THERAPY	   73.2	   7.5	   70.3	   8.3	   71.6	   7	   71.1	   6.5	   70.8	   8.4	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Heart	  -­‐	  Left	  Ventricular	  Mass	  
At	  GLM	   including	   as	   covariates	   age,	   sex,	   and	  DBP	   at	   baseline,	   LVM	  normalized	   for	   BSA	   did	   not	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LVM NORMALIZED FOR BSA 
	  
Tab.	  22	  LVM	  normalized	  for	  BSA	  g/m2	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   114,7	   16,7	   127,9	   25,7	   118,6	   14,9	   115,4	   14	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At	  GLM	  including	  as	  covariates	  age,	  sex,	  DBP,	  and	  LVM	  at	  baseline,	  LVM	  normalized	  for	  height	  was	  


































Tab.	  23	  LVM	  normalized	  for	  height	  (g/m2.7)	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   52.2	   7.7	   52.2	   7.7	   54.1	   6.6	   49.5	   6.6	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At	  GLM	  including	  as	  covariates	  age	  and	  DBP	  at	  baseline,	  relative	  wall	  thickness	  did	  not	  differ	  in	  the	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Tab.	  24	  Relative	  wall	  thickness	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	   3	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   0.55	   0.15	   0.51	   0.06	   0.49	   0.06	   0.48	   0.08	   0.43	   0.001	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Heart	  –	  Diastolic	  dysfunction	  	  
At	   GLM	   including	   as	   covariates	   age	   and	   DBP	   at	   baseline,	   E/E’	   was	   lower	   in	   the	   PTRAS	   group	  
























p = 0.011 
	  
	  
Tab.	  25	  E/E’	  
	  
BASELINE	   6	  MONTHS	   1	  YEAR	   2	  YEARS	  
mean	   SD	   mean	   SD	   mean	   SD	   mean	   SD	  
MEDICAL	  THERAPY	   8.9	   0.6	   9.8	   1.8	   10.5	   1.4	   8.6	   0.3	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DISCUSSION	  
1.	  Novelty	  of	  METRAS	  study	  
The	  novelty	  of	  the	  METRAS	  study	  includes	  the	  assessment	  of	  the	  two	  kidneys	  function	  separately	  
as	   primary	   endpoint	   rather	   than	   an	   index	   of	   global	   renal	   function	   as	   carried	   out	   in	   previous	  
trials33,37-­‐39,41,42	   (reciprocal	  of	   serum	  creatinine	  or	  eGFR).	   	  None	  of	   the	  previous	   trials	  considered	  
the	  GFR	  separately	  in	  the	  two	  kidneys	  as	  primary	  endpoint.	  	  This	  is	  an	  important	  issue	  in	  particular	  
for	  unilateral	  renal	  artery	  stenosis	  (all	  patients	  included	  to	  date	  in	  the	  METRAS	  trial	  have	  unilateral	  
stenosis).	   	   In	   fact,	   it	   is	  well	   known	   that	   in	   significant	  unilateral	   stenosis	   the	  GFR	  of	   the	   ischemic	  
kidney	   is	   lower	   compared	   to	   the	  hyperfiltration	   in	   the	   contralateral	   kidney	  exposed	   to	   a	  higher	  
blood	  pressure;	  after	  PTRAS,	  with	  BP	  decrease,	  the	  filtration	  in	  the	  unaffected	  kidney	  declines	  and	  
consequently	  total	  GFR	  remains	  stable.	   	  Therefore,	   indexes	  of	  global	  renal	   function	  as	  eGFR	  and	  
reciprocal	  of	  serum	  creatinine	  are	  endpoints	  not	  well	  suited	  to	  detect	  a	  change	  of	  renal	  function	  in	  
unilateral	  RAS	  (Fig.	  29).	  	  This	  was	  already	  reported	  in	  2004	  by	  Coen	  et	  al57,	  who	  demonstrated	  in	  
an	   analysis	   of	   the	   separate	   renal	   function	   in	   unilateral	   RAS	   that	   after	   PTRAS	   an	   increase	   in	   the	  
percentage	  of	  total	  GFR	  in	  the	  affected	  kidney	  occurred,	  with	  ensuing	  decrease	  in	  the	  filtration	  of	  
the	  contralateral	  kidney.	  	  Coen	  et	  al	  attributed	  the	  decrease	  in	  contralateral	  kidney	  function	  to	  the	  
decline	   of	   ultrafiltration	   in	   the	   non-­‐stenotic	   kidney	   after	   revascularization	   of	   the	   affected	   renal	  
artery.	  	  Moreover,	  hemodynamic	  factors	  following	  the	  decreased	  RAAS	  activity	  might	  be	  involved,	  
as	  suggested	  by	  the	  significant	  fall	  in	  systolic	  and	  diastolic	  blood	  pressure	  after	  the	  procedure57.	  	  It	  
has	   to	   be	   underlined	   that	   all	   previous	   RCTs	   had	   chosen	   as	   endpoints	   indexes	   of	   global	   renal	  
function:	   creatinine	   clearance	   in	   EMMA33,	   STAR41	   and	   CORAL39,	   serum	   creatinine	   in	   SNRASCG42	  
and	  CORAL39,	  mean	  slope	  of	  the	  reciprocal	  of	  serum	  creatinine	  in	  ASTRAL37.	  
Another	   important	   novelty	   in	   METRAS	   trial	   is	   the	   modality	   of	   assessment	   of	   the	   renal	   artery	  
stenosis.	   	   All	   the	   previous	   RCTs33,37-­‐39,41,42	   evaluated	   the	   degree	   of	   stenosis	   by	   means	   of	   CT	   or	  
angiography	  with	  a	  biplanar	  measurement	  based	  on	  diameter	  of	  the	  renal	  artery.	  	  In	  the	  METRAS	  
study	  the	  assessment	  of	  percentage	  of	  stenosis	  is	  performed	  by	  means	  of	  the	  reduction	  of	  lumen	  
in	   cross	   sectional	   area.	   	   This	   type	   of	   measurement	   is	   more	   accurate	   in	   evaluation	   of	   stenosis	  
because	  it	  is	  not	  affected	  by	  error	  measurements	  in	  eccentric	  plaques.	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Fig.	  29.	  Evolution	  of	  percent	  GFR	   in	  the	  stented	  and	  contralateral	  kidneys.	  *Significance	  of	  the	  difference	  
compared	  to	  basal	  value	  (p<0.05)57.	  
2.	  Effects	  on	  primary	  endpoint:	  improvement	  of	  ischemic	  kidney	  function	  with	  PTRAS	  
The	  primary	  objective	  of	  the	  METRAS	  study	  was	  to	  determine	  if	  PTRAS	  was	  superior	  or	  equivalent	  
to	   optimal	  medical	   treatment	   in	   preserving	   the	  GFR	   in	   the	   ischemic	   kidney	   by	  means	   of	   99mTc-­‐
DTPA	  scintigraphy.	   	  The	  crucial	   issue	  was	  the	   importance	  of	  restoring	  blood	  flow	  in	  the	   ischemic	  
kidney	   and	   its	   evaluation	   by	   means	   of	   GFR	   as	   assessed	   at	   renal	   scintigraphy,	   not	   only	   for	  
preservation	   of	   renal	   function	   in	   ischemic	   kidney	   but	   also	   for	   the	   benefits	   in	   the	   contralateral	  
organ.	   	   Indeed,	   an	   important	   observation	   was	   that	   pathways	   of	   injury	   in	   a	   stenotic	   kidney	  
contribute	  to	  significant	  risks	  for	  the	  non-­‐stenotic	  kidney,	  the	  cardiovascular	  system,	  and	  arterial	  
pressure.	   	   The	   post-­‐stenotic	   kidney	   in	   both	   animals	   and	   humans	   releases	   inflammatory	   injury	  
signals58-­‐60,	   and	   their	   levels	   rise	   not	   only	   in	   the	   stenotic	   but	   also	   in	   the	   contralateral	   kidney,	  
suggesting	   reno-­‐renal	   crosstalk	   and	   systemic	   effects	   of	   ARAS.	   	   Consequently,	   damage	   and	  
inflammatory	   markers	   in	   the	   contralateral	   kidney	   are	   greater	   than	   those	   induced	   by	   simple	  
nephrectomy	  or	  even	  angiotensin-­‐II	  infusion61.	  	  Furthermore,	  cardiac	  hypertrophy	  and	  dysfunction	  
are	  magnified	  in	  patients	  with	  RVH	  compared	  with	  essential	  hypertension62.	  	  	  
The	  METRAS	   study	   demonstrated	   that	   GFR	   in	   the	   ischemic	   kidney	   increases	   progressively	   after	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PTRAS	  compared	  to	  the	  medical	  therapy	  group,	  in	  which	  GFR	  remains	  stable.	  	  These	  results	  were	  
significantly	  different	  (p	  =	  0.048)	  when	  the	  GFR	  was	  estimated	  by	  means	  of	  the	  CKD-­‐EPI	  formula	  
and	   the	   filtration	  of	   the	   ischemic	   kidney	  determined	  at	  NAFS	   (method	  B)	   that	   is	  more	   accurate	  
compared	   to	   the	   assessment	   of	   the	   GFR	   directly	   at	   NAFS	   (method	   A),	   which	   was	   borderline	  
significant	   (p	   =	   0.07).	   	  METRAS	   trial	   is	   the	   first	   RCT	   evaluating	   the	   function	   in	   the	   two	   kidneys	  
separately	  assessed	  at	  NAFS.	   	  There	   is	  only	  one	  prospective	  trial,	  above	  mentioned,	   in	  whom	  27	  
patients	  with	  unilateral	  RAS	  underwent	  stenting	  and	  19	  patients	  remained	  on	  medical	  treatment,	  
who	  were	  followed	  for	  1	  year	  to	  assess	  the	  variation	  of	  GFR	  in	  the	  two	  kidneys	  separately57	  (Fig.	  
29).	  	  METRAS	  trial	  confirms	  the	  results	  reported	  by	  Coen	  et	  al	  in	  whom	  in	  the	  stented	  kidneys	  GFR	  
increased	  significantly.	  
These	  results	  are	  interesting	  considering	  the	  small	  number	  of	  patients	  enrolled	  to	  date	  in	  METRAS	  
trial	  (10	  in	  the	  endovascular	  and	  8	  in	  the	  medical	  therapy	  group).	  	  The	  initial	  power	  calculation	  of	  
the	  METRAS	   trial	   showed	   that	   at	   least	   60	   patients	   per	   arm	  were	  needed	   to	   reach	   an	   adequate	  
statistic	  power.	  	  Moreover,	  it	  should	  be	  considered	  that	  not	  all	  the	  patients	  completed	  the	  follow-­‐
up.	   	  The	  analysis	  with	  method	  B	  excluding	  T6,	   in	  whom	  the	  number	  of	  patients	  was	  very	   small,	  
proved	  the	  difference	  to	  be	  even	  more	  significant	  (p=0.027)	  (Fig.	  10).	  	  
In	  the	  unaffected	  kidney	  the	  GFR	  remained	  stable	  during	  time	  in	  both	  arms	  (Fig.	  11).	  	  In	  our	  study	  
we	  could	  not	  confirm	  the	  reduction	  in	  hyperfiltration	  post-­‐PTRAS	  as	  reported	  by	  Coen57.	  	  	  
3.	  Effects	  on	  secondary	  endpoint:	  global	  renal	  function	  
Global	  renal	  function	  was	  evaluated	  by	  means	  of	  GFR	  assessed	  at	  NAFS	  and	  estimated	  by	  CKD-­‐EPI	  
formula,	  serum	  creatinine,	  and	  serum	  cystatin-­‐c.	  	  Global	  GFR	  at	  NAFS	  and	  eGFR	  were	  similar	  in	  the	  
two	   arms	   at	   follow-­‐up	   (Fig.	   12	   and	   16).	   	   After	   2	   years	   of	   follow-­‐up	   creatinine	   and	   cystatin-­‐c	  
decreased	   in	   the	   PTRAS	   compared	   to	   the	  medical	   therapy	   group,	   in	  whom	   it	   increased	   (serum	  
creatinine	  from	  89.3	  to	  98.2	  mcmol/L	  in	  medical	  group	  and	  from	  73.4	  to	  70.2	  mcmol/L	  in	  PTRAS	  
group,	  p=0.035;	   cystatin-­‐c	   from	  0.8	   to	  0.9	  mg/L	   in	  medical	   group	  and	  0.8	   to	  0.7	  mg/L	   in	  PTRAS	  
group,	  p=0.02)	  (Fig.	  17	  and	  18).	  	  Cystatin-­‐c,	  a	  marker	  of	  renal	  function	  whom	  serum	  concentration	  
depends	  on	  glomerular	  filtration	  and	  is	  not	  influenced	  by	  gender,	  age,	  and	  muscle	  mass,	  is	  more	  
accurate	  than	  creatinine	  to	  assess	  global	  renal	  function.	  	  
These	   results	   are	   interesting	   compared	   to	   data	   reported	   from	   previous	   RCTs.	   	   In	   fact,	   none	   of	  
them	  demonstrated	  an	  improvement	  in	  terms	  of	  global	  renal	  function	  in	  PTRAS	  group.	   	  EMMA33	  
failed	  to	  demonstrate	  a	  difference	  between	  groups	  in	  GFR	  calculated	  with	  Cockcroft	  formula	  at	  6	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months	  follow-­‐up	  (p=0.73).	  	  Scottish	  trial42	  observed	  no	  significant	  differences,	  or	  trend	  in	  serum	  
creatinine	  between	  or	  within	  the	  groups	  during	   follow-­‐up	  (192	  vs.	  152	  mcmol/L	   in	  endovascular	  
and	  medical	  arm	  respectively	   in	  bilateral	   stenosis	  and	  146	  vs.	  168	  mcmol/L	   in	  endovascular	  and	  
medical	  arm	  respectively	  in	  unilateral	  stenosis).	  	  The	  Dutch	  trial38	  showed	  a	  difference	  in	  terms	  of	  
serum	  creatinine	  and	  GFR	  estimated	  between	  the	  groups	  at	  3	  months	  follow-­‐up	  (serum	  creatinine	  
1.2	  vs.	  1.3	  mg/dl	  in	  endovascular	  and	  medical	  arm	  respectively;	  p=0.03	  and	  GFR	  70	  vs.	  59	  ml/min	  
in	  endovascular	  and	  medical	  arm,	  respectively;	  p=0.05)	  but	  it	  was	  not	  confirmed	  at	  1	  year	  follow-­‐
up	  (serum	  creatinine	  1.3	  vs.	  1.2	  mg/dl	  in	  endovascular	  and	  medical	  arm,	  respectively,	  and	  GFR	  58	  
vs.	   65	  ml/min	   in	   endovascular	   and	  medical	   arm	   respectively;	   p=0.11	   for	   both).	   	   The	  Dutch	   trial	  
performed	  also	   renal	   scintigraphy	  with	  use	  of	   technetium-­‐99m-­‐labeled	  mercaptoacetyltriglycine,	  
but	   they	   reported	   only	   the	   results	   in	   terms	   of	   the	   probability	   of	   renovascular	   disease	   (low,	  
indeterminate,	   or	   high)	   and	   not	   the	   total	   and	   separate	   GFR	   in	   the	   two	   kidneys38.	   	   STAR	   trial41	  
considered	   as	   primary	   endpoint	   the	   worsening	   of	   renal	   function,	   defined	   as	   a	   20%	   or	   greater	  
decrease	   in	   estimated	   creatinine	   clearance	   according	   to	   the	   Cockcroft	   and	   Gault	   formula,	  
compared	  with	  baseline,	  based	  on	  2	  repeated	  measurements.	  	  Difference	  between	  groups	  did	  not	  
reach	   the	   significance.	   	  ASTRAL	   trial37	   reported	  during	   the	  5-­‐year	   study	  period,	   an	  overall	  mean	  
slope	  of	  the	  reciprocal	  of	  the	  serum	  creatinine	  concentration	  of	  −0.07×10−3	  liters	  per	  micromole	  
per	   year	   in	   the	   revascularization	   group,	   as	   compared	  with	   −0.13×10−3	   liters	   per	  micromole	  per	  
year	   in	   the	   medical-­‐therapy	   group,	   results	   borderline	   significant	   favoring	   revascularization	  
(p=0.06).	  	  However,	  the	  mean	  serum	  creatinine	  level	  did	  not	  reach	  the	  significance.	  	  The	  authors	  
performed	  also	  a	  per-­‐protocol	  analysis	  and	  a	  post	  hoc	   subgroup	  analysis	  between	  patients	  with	  
severe	  anatomical	  disease	  (bilateral	  renal-­‐artery	  stenosis	  of	  more	  than	  70%	  and	  with	  renal-­‐artery	  
stenosis	   of	   more	   than	   70%	   in	   a	   single	   functioning	   kidney)	   and	   patients	   without	   such	   severe	  
anatomical	   disease,	   but	   they	   also	   found	   no	   significant	   differences	   in	   the	   primary	   outcome37.	  	  
However,	   significant	   design	   flaws	   and	   selection	  bias	   affect	  many	  of	   these	   studies63,	   limiting	   the	  
usefulness	  of	  available	  data,	  as	  previously	  mentioned	  in	  the	  background	  paragraph.	  	  	  
It	  is	  interesting	  that	  only	  METRAS	  trial	  evaluated	  global	  renal	  function	  by	  means	  of	  GFR	  estimated	  
at	  NAFS	  and	  is	  the	  first	  RCT	  that	  considered	  renal	  function	  expressed	  as	  level	  of	  cystatin-­‐c.	  	  
4.	  Effects	  on	  secondary	  endpoint:	  blood	  pressure	  control	  
The	   METRAS	   trial	   demonstrated	   a	   better	   BP	   control	   in	   the	   PTRAS	   arm	   considering	   DBP	   and	  
number	  of	  antihypertensive	  drugs	  (Fig.	  14	  and	  15).	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The	  mean	  24	  hours	  DBP	  assessed	  at	  ABPM	  decreased	  in	  PTRAS	  group	  at	  3	  years	  follow-­‐up	  (63	  vs.	  
70	  mmHg	  in	  the	  endovascular	  arm	  and	  the	  medical	  arm,	  respectively;	  p=0.029)	  despite	  a	  reduction	  
in	   the	   number	   of	   hypertensive	   drugs	   (2.4	   vs.	   4.5	   in	   the	   endovascular	   and	   the	   medical	   arm,	  
respectively;	   p=0.055).	   	   Although	   the	   GLM	   for	   the	   number	   of	   drugs	   was	   borderline	   significant	  
(p=0.055),	  the	  ANOVA	  test	  revealed	  a	  decreased	  number	  of	  drugs	  in	  the	  PTRAS	  group	  at	  3	  months,	  
1	  year,	  and	  2	  years	  compared	  to	  the	  medical	   therapy	  group	  (p=0.047	  at	  6	  months,	  p=0.016	  at	  1	  
year,	  and	  p=0.048	  at	  2	  years)	  (Figure	  15).	  	  We	  would	  like	  to	  underline	  that	  patients	  available	  at	  3	  
years	  follow-­‐up	  are	  few	  and	  this	  could	  have	  affected	  the	  results.	  	  	  
The	   decrease	   of	   DBP	   and	   number	   of	   antihypertensive	   drugs	   in	   the	   PTRAS	   group	   highlights	   the	  
favorable	   effect	   of	   the	   revascularization	   procedure	   in	   ARAS	   patients	   and,	   if	   this	   trend	   will	   be	  
confirmed	   upon	   completion	   of	   the	   trial,	   it	   will	   translate	   in	   a	   better	   compliance	   of	   patients	   to	  
therapy	  and	  possibly	  to	  a	  reduction	  of	  cost	  for	  National	  Healthcare	  System.	  	  
The	  benefit	  of	  revascularization	  in	  ARAS	  on	  BP	  control	  has	  been	  demonstrated	  in	  some	  RCTs	  and	  in	  
a	   recent	  meta-­‐analysis45.	   Plouin	   et	   al	   in	   EMMA	   trial33	   reported	   a	   reduction	   in	   number	   of	   drugs	  
expressed	  as	  defined	  daily	  doses	  in	  the	  PTRAS	  group	  compared	  to	  the	  medical	  group	  (1.0	  vs.	  1.78	  
respectively,	  p=0.009)	  during	  6	  months	  follow-­‐up.	  	  Dutch	  study38	  also	  showed	  a	  difference	  in	  drugs	  
in	   endovascular	   and	   medical	   group	   at	   1	   year	   follow-­‐up	   (1.9	   vs.	   2.4	   respectively,	   p=0.02).	   	   In	  
SNRASG	  trial42,	  Webster	  et	  al	  reported	  lower	  BP	  values	  in	  bilateral	  stenosis	  in	  endovascular	  group	  
compared	   to	  medical	   treatment	   (152/83	  vs.	  171/91	  mmHg	   respectively,	  p<0.01)	  and	   in	   recently	  
published	   CORAL	   trial39,	   SBP	   resulted	   lower	   in	   PTRAS	   group	   compared	   to	  medical	   therapy	   (-­‐2.3	  
mmHg,	  p=0.03).	  
Recently	  published	  meta-­‐analysis45-­‐48,	  showed	  that	  PTRAS	  seems	  to	  have	  a	  small	  drug-­‐saving	  effect	  
and	  may	  result	  in	  a	  small	  improvement	  in	  diastolic	  BP.	  	  These	  results	  are	  concordant	  with	  our	  data.	  
5.	  Effects	  on	  secondary	  endpoint:	  metabolic	  control	  
The	  METRAS	  study	  demonstrated	  a	  decrease	  of	  glycosylated	  hemoglobin	  in	  patients	  treated	  with	  
PTRAS.	   	  Although	  the	  two	  groups	  had	  different	  levels	  of	  glycosylated	  hemoglobin	  at	  baseline	  (47	  
mmol/mol	   in	   the	  medical	   therapy	   vs.	   41	  mmol/mol	   in	   the	   PTRAS	   group),	  we	  performed	   a	  GLM	  
analysis	  including	  as	  covariates	  the	  percentage	  of	  diabetic	  patients	  at	  baseline	  and	  baseline	  levels	  
of	  glycosylated	  hemoglobin.	  	  At	  3	  years	  follow-­‐up	  glycosylated	  hemoglobin	  was	  lower	  in	  the	  PTRAS	  
compared	  to	  the	  medical	  arm,	  in	  whom	  values	  tended	  to	  increase	  (from	  47	  to	  47.7	  mmol/mol	  in	  
medical	  group	  and	  from	  41.3	  to	  40.3	  mmol/mol	  in	  PTRAS	  group,	  p=0.034)	  (Fig.	  20).	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LDL,	  HDL,	   total	   cholesterol,	   and	   triglycerides	  were	   similar	   across	  groups,	  probably	  because	  both	  
arms	   at	   randomization	   and	   during	   the	   trial	  were	   aggressively	   treated	  with	   lipid-­‐lowering	   drugs.	  	  
Similarly,	  homocysteine	  was	  comparable	  between	  arms,	  which	  was	  not	  unexpected	  being	  a	  level	  
exceeding	  15	  mcmol/L	  an	  exclusion	  criterion	  (Fig.	  19	  and	  21).	  
6.	  Target	  organ	  damage	  
The	  METRAS	  study	  assessed	  renal	  and	  cardiac	  organ	  damage.	  
Patients	  treated	  with	  PTRAS	  had	  lower	  renal	  damage	  assessed	  by	  means	  of	  microalbuminuria.	  	  It	  is	  
worth	  highlighting	  that	  at	  2	  years	  time-­‐point	  microalbuminuria	  was	  higher	  in	  the	  medical	  therapy	  
arm	  probably	  because	  of	  one	  patient	  with	  uncompensated	  diabetes	  mellitus	  and	  urinary	  infection	  
with	  a	  transient	  increase	  of	  microalbuminuria.	  	  However,	  after	  exclusion	  of	  the	  2	  years	  time-­‐point,	  
the	  level	  of	  microalbuminuria	  increases	  in	  medical	  therapy	  group	  while	  appears	  stable	  with	  time	  in	  
the	  PTRAS	  group	  (Fig.	  22).	  	  
In	   the	  METRAS	   study	   design	   resistive	   index	   was	   not	   an	   inclusion	   criterion	   to	   avoid	   a	   potential	  
confounder.	   	   At	   follow-­‐up	   patients	   treated	   with	   PTRAS	   showed	   an	   increased	   RI	   from	   baseline	  
compared	  to	  medical	  therapy.	  	  This	  effect	  might	  be	  explained	  by	  an	  increased	  RI	  due	  to	  removal	  of	  
the	   stenosis	   in	   the	   treated	  kidney	  after	   the	  procedure.	   	  On	   the	  other	  hand,	   analyzing	   the	   time-­‐
course	   of	   RI	   in	   contralateral	   kidney	   no	   between	   group	   differences	   could	   be	   detected	   and	   RI	  
appeared	  stable	  (Fig.	  23	  and	  24).	  	  
Cardiac	  damage	  was	  evaluated	  at	  echocardiography	  assessing	  LVMI	  for	  BSA	  and	  height.	  	  We	  found	  
a	  regression	  of	  LVH	  in	  both	  groups	  during	  3	  years	  follow-­‐up	  (from	  52.2	  to	  47.5	  and	  from	  50.1	  to	  
47.8	  g/m2.7	   in	   the	  medical	  and	  endovascular	  group,	   respectively),	  but	   there	  were	  no	  differences	  
between	  groups	  in	  terms	  of	  regression	  of	  LVH,	  although	  the	  LVM	  indexing	  for	  height	  seems	  to	  be	  
lower	   in	  PTRAS	  group	  at	   follow-­‐up	   (borderline	   significant	  p=0.058).	   	   In	  both	  groups	   there	  was	  a	  
reduction	  in	  relative	  wall	  thickness	  (from	  0.55	  to	  0.43	  in	  the	  medical	  therapy	  and	  from	  0.49	  to	  0.39	  
in	  the	  PTRAS	  group)	  (Fig.	  25,	  26	  and	  27).	  	  
Diastolic	   dysfunction,	   assessed	   as	   E/E’,	   decreased	   in	   the	   PTRAS	   compared	   to	   the	   medical	   arm	  
(p=0.011)	   (Fig.	  28).	   	  The	   improvement	   in	  diastolic	   function	   in	   the	  PTRAS	  group	  might	   reflect	   the	  
improved	  DBP	  control	  in	  this	  group	  during	  time.	  	  
These	  results	  are	  consistent	  with	  those	  of	  RAS-­‐CAD	  trial,	  a	  clinical	  trial	  aimed	  at	  testing	  whether	  
renal	  artery	  revascularization,	  compared	  with	  medical	  therapy,	  affects	  left	  ventricular	  hypertrophy	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progression.	  	  It	  included	  84	  patients	  randomly	  assigned	  to	  the	  revascularization	  arm	  (43	  patients)	  
and	   to	   the	   medical	   therapy	   arm	   (41	   patients).	   	   The	   authors	   found	   that	   there	   was	   a	   mild	   but	  
statistically	  significant	  regression	  of	  left	  ventricular	  mass	  in	  patients	  on	  medical	  therapy	  and	  those	  
who	   underwent	   renal	   revascularization.	   	   In	   patients	   on	  medical	   therapy,	   LVM	   indexed	   to	   body	  
surface	  area	  (LVMI)	  decreased	  from	  113	  to	  107	  g/m2	  after	  1	  year	  (ΔLVMI,	  -­‐6.1;	  95%	  CI,	  -­‐11.4	  to	  -­‐
0.8	  g/m2;	  p=0.03).	  	  This	  change	  was	  similar	  (p=0.6)	  to	  that	  registered	  in	  the	  revascularization	  arm,	  
from	  124	  at	  baseline	  to	  116	  g/m2	  at	  1	  year	  (ΔLVMI,	  -­‐8.2;	  95%	  CI,	  -­‐14.3	  to	  -­‐2.1	  g/m2;	  p=0.01)64.	  	  	  
7.	  Limitations	  and	  strengths	  of	  the	  study	  
The	  METRAS	  study	  has	  some	  limitations	  that	  deserve	  to	  be	  mentioned.	  	  	  
First	  of	  all,	  as	  above	  stated,	  the	  number	  of	  patients	  enrolled	  is	  limited.	  	  In	  the	  design	  of	  the	  study,	  
the	  minimum	  number	  of	  patients	  in	  each	  arm	  was	  planned	  to	  be	  sixty,	  instead	  we	  enrolled	  only	  10	  
patients	  in	  PTRAS	  and	  8	  in	  medical	  group.	  	  
This	   could	   be	   explained	   in	   part	   by	   the	   strict	   enrollment	   criteria,	   which	   require	   a	   predefined	  
percentage	  of	  atherosclerotic	  stenosis	  and	  exclude	  patients	  with	  compelling	  indication	  to	  PTRAS.	  	  
In	   fact,	   among	   30	   patients	   evaluated	   for	   trial	   inclusion,	   only	   20	   were	   eligible.	   	   Moreover,	   the	  
METRAS	   trial	  was	   originally	   conceived	   as	   a	  multicentric	   trial,	   but	   none	   of	   the	   centers	   originally	  
involved	   in	   study	   design	   concurred	   to	   patient	   enrolment.	   	  Major	   issues	  were	   the	  ASTRAL37	   and	  
more	  recently	  CORAL39	  trials	  results,	  which	  discouraged	  PTRAS	  procedure	  except	  in	  patients	  with	  
compelling	  indications	  to	  PTRAS.	  
Among	  the	  most	  important	  problems	  in	  METRAS	  trial,	  which	  might	  also	  explain	  the	  lack	  of	  patients	  
enrolment	  in	  other	  centers,	  is	  the	  complexity	  of	  the	  trial	  due	  to	  the	  number	  of	  tests	  and	  follow-­‐up	  
visits	  required,	  particularly	  during	  the	  first	  year	  (planned	  at	  baseline,	  after	  4-­‐8	  weeks,	  at	  1	  month,	  
3	  months,	  6	  months,	  1	  year).	  	  Patients	  often	  complained	  about	  the	  numerous	  tests	  requested	  and,	  
among	  others,	  about	  NAFS,	  which	  was	  erroneously	  perceived	  as	  a	  “dangerous	  exam”.	  	  ARAS	  is	  an	  
asymptomatic	   disease	   and	   patients	   often	   hesitate	   to	   be	   adherent	   to	   follow-­‐up	   compared	   to	  
diseases	  greatly	  affecting	  quality	  of	  life.	  	  Moreover,	  the	  majority	  of	  patients	  were	  referred	  to	  our	  
center	   and	   lived	   far	   from	  Padua	  with	   logistic	  problems	  with	   visits,	   particularly	  old	  patients	  with	  
limited	  mobility.	  	  In	  addition,	  the	  cost	  of	  the	  trial	  was	  covered	  by	  the	  Healthcare	  system	  only	  for	  a	  
subset	   of	   patients,	   because	   the	   tests	   were	   considered	   part	   of	   a	   standard	   follow-­‐up	   in	   patients	  
undergoing	   PTRAS.	   	   Thus,	   patients	   who	   were	   required	   to	   pay	   out	   of	   their	   pocket,	   had	   poor	  
compliance	  to	  follow-­‐up	  tests	  and	  visits	  due	  to	  excessive	  costs,	  which	  explains	  the	  non-­‐trivial	  drop	  
out	   rate	   (10%).	   	   In	   particular,	   cystatin-­‐c	   is	   a	   not	   reimbursable	   exam	   from	   National	   Healthcare	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System,	  and	  the	  patient	  had	  to	  pay	  all	  the	  cost	  of	  the	  exam.	  	  This	  was	  a	  not	  negligible	  problem	  for	  
adherence	  to	  follow-­‐up	  visits	  and	  exams	  of	  patients	  in	  our	  trial	  and	  for	  this	  reason	  the	  cystatin-­‐c	  
available	  values	  at	  each	  time-­‐point	  are	  fewer	  compared	  to	  other	  blood	  exams.	  	  
Finally,	   the	   METRAS	   study	   did	   not	   assess	   major	   clinical	   endpoints	   as	   cardiovascular	   and	   renal	  
events	   and	   deaths	   because	   the	   patients	   required	   to	   assess	   these	   end-­‐points	   far	   exceeded	   the	  
number	  that	  was	  reasonable	  to	  expect	  to	  enroll	  in	  such	  a	  thorough	  trial.	  
In	   the	  METRAS	  study,	  one	  strong	  point	   is	   the	  standardization	  of	   therapy	  at	  baseline	   in	  order	   to	  
obtain	   a	   strict	   control	   of	   BP	   and	   metabolic	   parameters	   in	   both	   groups,	   in	   addition	   to	  
randomization,	   assured	   a	   homogeneity	   between	   groups	   at	   baseline	   (as	   showed	   by	   the	  
characteristics	   of	   the	   cohort	   at	   baseline	   in	   table	   6	   in	  whom	   there	   are	  no	  difference	   at	   baseline	  
between	   medical	   and	   endovascular	   group).	   	   This	   permitted	   a	   balanced	   comparison	   between	  
groups	   and	   this	   uniformity	   could	   have	   emphasized	   the	   difference	   between	   groups	   during	   time,	  
difference	  not	  demonstrated	  in	  previous	  trials.	  	  
Furthermore,	   in	   METRAS	   study	   our	   center	   had	   the	   availability	   of	   a	   first	   level	   radiology,	   which	  
allowed	  an	  accurate	  evaluation	  of	  grade	  of	  stenosis	  by	  means	  of	  the	  assessment	  of	  cross	  sectional	  
area	  with	  a	  specific	  software	  and	  not	  on	  the	  basis	  of	  a	  biplane	  measurement,	  as	  all	  the	  previous	  
trials.	  	  Moreover,	  the	  percentage	  of	  complications	  (0%)	  and	  the	  success	  rate	  (100%)	  of	  procedure	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CONCLUSIONS	  
Our	  study	  demonstrated	  an	  improvement	  in	  GFR	  in	  ischemic	  kidney	  in	  patients	  treated	  with	  PTRAS	  
in	   association	   to	   optimal	   medical	   therapy	   compared	   to	   patients	   treated	   with	   medical	   therapy	  
alone.	  	  
Patients	   treated	   with	   PTRAS	   showed	   an	   improvement	   of	   DBP	   control	   in	   spite	   of	   a	   decreased	  
number	  of	  	  antihypertensive	  drugs	  during	  3	  years	  follow-­‐up.	  
Index	  of	  global	  renal	  function	  (serum	  creatinine	  and	  cystatin-­‐c)	  and	  glycemic	  control	  (glycosylated	  
hemoglobin)	  appeared	  to	  improve	  in	  PTRAS	  compared	  to	  medical	  therapy	  group.	  	  
Diastolic	   dysfunction	   showed	   a	   regression	   in	   PTRAS	   patients	   compared	   to	   medical	   treated	  
patients.	  	  
In	  my	  view	  these	   results	  are	  encouraging	  and	  suggest	   the	  need	  to	  continue	   the	   trial	   in	  order	   to	  
confirm	  them	  with	  higher	  number	  of	  patients	  and	  longer	  follow-­‐up.	  
